

AUTHOR INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (March 2003), Supplement 2 (April 2003), Supplement 3 (April 2003), Supplement 4 (April 2003), and Supplement 5 (June 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Aaron, L., E13
Abbott, K.C., 796, 1267
Abraham, W.T., 571
Agarwal, R., 651, 752
Agodoa, L.Y., 796, 1267
Ahmad, S., S4:44
Ahuja, T.S., 279, 1060
Akagi, S., 624
Akbari, A., E17
Akkaya, V., 616
Al Ajami, A., 709
Al Arrayed, A., 709
Albaqali, A., 709
Albright, R.C., 702
Al Mahrroos, H., 709
Almond, M.K., 776
Alongi, G., 1278
Altimari, A., 1303
Álvarez-Ude, F., E9
Ando, T., 972
Ansari, A., 523
Araki, I., 637
Aronoff, G.R., 433
Arrigo, G., 328
Arroyo, A., E9
Asakimori, Y., 822
Asif, A., E18
Asim, M., 696
Assadi, F., E3
Astor, B.C., 1
Atkins, R.C., 132, 596
Aubert, P., E20
Averbukh, Z., 196
Avni, Y., E2
Avorn, J., 84
Bacchetti, P., 162, 447
Bagiatoudi, G., E15
Bailey, J.L., 394
Bairaktari, E.T., 1225
Bajema, I.M., 532
Baker, R.J., 670
Bakker, S.J.L., 859
Bakris, G.L., 1267
Baldini, C.L., 95
Banerjee, D., E18
Bang, B.K., 422, E6
Bárány, P., 12122
Barenbrock, M., 1088
Bartlett, S.T., 849
Basilé, G., 1314
Bastacky, S., E7
Bazzi, C., 328
Beaufils, H., 1205
Becker, B.N., S4:27
Bedinger, M.R., 433
Behets, G.J., 997
Bender, W.L., 386
Berman, S., 196
Bernardini, J., 664
Bertelli, R., 1314
Berthoux, F., 558
Bervoets, A.R.J., 997
Bhandari, S., E1
Bhathena, D.B., 1179
Bianchi, S., 565
Bigazzi, R., 565
Bingham, J., 1322
Bisegna, S., 1278
Bleeker-Rovers, C.P., E22
Bletry, O., 1205
Bleyer, A.J., 990
Bliwise, D.L., 394
Bobelu, A., 1195
Bochenski, J., 1189
Bocquet, N., 550
Boelaert, J.R., 877
Boeschoten, E.W., 1293
Boletis, J.N., 29
Bondia, A., 488
Boomsma, F., 807
Booth, A.D., 776
Borgmann, S., 933
Bostom, A.G., 442
Boudville, N., 658
Bourgoignie, J.J., E18
Brackbill, E.L., E3
Braden, G.L., 1247
Bragg-Gresham, J.L., 605
Bridoux, F., 497
Brier, M.E., 433
Briganti, E.M., 596
Brophy, P.D., 984
Brown, E.A., 670
Broyer, M., 550
Brujin, J.A., 532
Bunchman, T.E., 984
Burke, G.L., 990
Burns, A., 776
Butani, L., 760
Buzzo, M., 1170
Caiazza, A., 565
Cain, J.A., 433
Campese, V.M., 565
Campolo, G., 1278
Canas, G., xl
Caplin, N., 429
Cardi, G., 95, 1314
Carnethon, M.R., 580
Carpenter, B., 212
Carroll, R.P., 676
Case, C., 1016
Chadban, S.J., 596
Chae, D.-W., 1037
Chaignon, M., E20
Chan, C., 225, 403
Chan, K.W., E21
Chan, M. H.-M., 250
Chang, I.J., 508
Chang, Y.S., 422
Chao, T.-Y., 1052
Chauveau, D., 550, 1205
Cheek, D.E., 1097
Cheong, H.I., 238
Cherr, G.S., 990
Cheunsuchon, B., 508, 1116
Chieco, P., 1303
Chiurchiu, C., E4
Chkhotua, A.B., 1303
Chng, W.J., 692
Cho, B.S., E6
Choi, B.S., E6
Choi, K.H., 943
Choi, S.J., E11
Choi, Y., 238
Choi, Y.H., E11
Choi, Y.J., 422, E6
Chong-Lopez, A., 696
Chow, F.Y.F., 596
Chow, K.-M., 250
Chu, P., 1052
Chuahirun, T., 13
Chung, W.K., 891
Clemenger, M., 670
Clopton, P., 571
Coché, E., E8
Cogné, M., 497
Cohen, N., 196
Cohn, M., 196
Collinge, N., 1060
Comper, W.D., 336
Concato, J., 105
Connaire, J., xli
Consugar, M., 90

Corbacho, L., 488
 Coresh, J., 1, 149
 Corey, H., 259
 Corstens, F.H.M., E22
 Cosnard, G., E8
 Coyne, D.W., 651
 Craven, T.E., 990
 Cruess, D., 796
 Curhan, G., 1240
 Curhan, G.C., 588, 643
 Curtin, R.B., 1286

D'Agati, V.D., 259, 714, 891, 1327
 Daghari, H., 1170
 Dagnino, M., 1314
 Dahl, N., 651
 Dahlstrom, L.R., 76
 D'Amico, G., 328
 Dams, G., 997
 Daphnis, E., 29
 Davis, C.L., 76
 Davison, D.L., E14
 Dean, R.H., 990
 Deaton, D., 1247
 De Broe, M.E., 997
 De Chazal, I., 702
 Decourt, C., 497
 de Jong, P.E., 733, 859
 de Jongh, S., 684
 Dekker, F.W., 1293
 Delahousse, M., E20
 Dembinska-Kiec, A., 203
 De Pauw, R., 877
 Deray, G., 292
 D'Errico, A., 1303
 de Séaux, R.G.L., E22
 de Tovar, G., E20
 de Vries, A.P.J., 859
 DeVries, A.S., 877
 de Zeeuw, D., 733
 D'Haese, P.C., 997
 Dhiman, R.K., 709
 Diaz-Mitoma, F., 212
 Di Duca, M., 1314
 DiMauro, S., 259
 Dixit, M.P., E16
 Dooley, M.A., 455
 Doss, S., 1008
 Doyle, J., 171
 Duc, P., 571
 Dudley, R.A., 171
 Dumoulin, A., 38

Edwards, M.S., 990
 Efrati, S., 196
 Eggers, P.W., 433
 Eknoyan, G., 1, 868, S4:1, S5:3
 Elisaf, M.S., 1225
 El-Jazzar, K.M., E14
 El Kossi, M.M.H., 785
 Ellis, P., 776

El Nahas, A.M., 785
 Emma, F., 1314
 Emmett, M., 230
 Endisch, G., 933
 Endoh, M., 950
 Engelman, R., 1247
 Ertürk, S., 1233
 Eustace, J.A., 351
 Evans, A., S4:4
 Evans, S., 493

Fabrizi, F., 1278
 Fakhouri, F., 550, E13, 1205
 Falk, A., 429
 Falkenhain, M.E., 962
 Faratro, R., 225
 Farias, K.B., E16
 Fathi, R., 1016
 Feber, J., 212
 Federick, P.R., 433
 Fehrman-Ekhholm, I., 1212
 Ferluga, D., 539
 Fernández-Reyes, M.J., E9
 Ferrario, F., 532
 Ferraz, M.B., 186
 Ferris, M.E., 455
 Filler, G., 212
 Fink, N.E., 149
 Firrincieli, A., E4
 Fish, D.N., 269
 Fishbane, S., S5:1, 18
 Flack, J., 1247
 Flanigan, M.J., 840
 Flauto, R.P., 125
 Fogo, A.B., xxxii, 508, xlvi, i
 Folkert, V.W., 651
 Fordtran, J.S., 230
 Forget, C., 212
 Fortmann, S.P., 580
 Frankenfield, D.L., 433, 840
 Frederick, P., 840
 Fricke, H., 933
 Fridolin, I., 1026
 Fried, L., 664
 Friedman, A.N., 442, 480
 Fritz, B.A., 1008
 Fryer, A.A., 676
 Fujigaki, Y., E10
 Fujimi, S., 972
 Fukasawa, M., 637
 Fukuda, K., 371
 Fulladosa, X., 1065
 Fusaroli, M., E4

Gabor, J.Y., 403
 Gabusi, E., 1303
 Gagnadoux, M.-F., 550
 Galperin, E., 196
 Gangarossa, S., 95
 Gans, R.O.B., 733, 859
 Garcia, P., 488

Garrido, J., 488
 Garvin, J., 891
 Gaskin, G., 776
 Geiger, X., 1116
 Genchallac, H., 616
 Germain, M., 1247
 Gesto, R., E9
 Ghiggeri, G.M., 95, 1314
 Ghuloom, A., 709
 Giatromanolaki, A., 360
 Ginevri, F., 1314
 Gipson, D.S., 455
 Godbole, M., 1163
 Goldfarb, D.S., 220
 Goldsmith, D., 493, 523
 Goldsmith, D.J.A., 1322
 Goldstein, M., E12
 Goldstein, S.L., 984
 Golper, T.A., S4:27
 Goodkin, D.A., 605
 Goral, S., S4:27
 Gordon, I., 493
 Grady, J., 1060
 Greene, T., 1, 962
 Gregory, M.J., 984
 Grigioni, W.F., 1303
 Grinyó, J.M., 1065
 Grünfeld, J.-P., 550, E13, 1205
 Guery, B., E13
 Guirl, M.J., 230
 Gulati, K., 1163
 Gulati, S., 1163
 Gupta, M., 212

Ha, I.S., 238
 Ha, S.-K., 943
 Hacker, U.T., 933
 Haenebalcke, C.W., 877
 Hagen, C., 532
 Hahn, H., 238
 Hall, A.V., 1140
 Haluska, B., 1016
 Han, D.S., 943
 Hanly, P.J., 403
 Hansen, K.J., 990
 Harden, P.N., 676
 Hariachar, S., 742
 Harris, P.C., 90
 Hartikainen, J., 1219
 Haruki, S., 1155
 Hata, J.-i., 1110
 Hataya, H., 1110
 Hatzidimou, K.G., 1225
 Hauer, H.A., 532
 Haugen, E.N., 702
 Hausberg, M., 1088
 Hawley, C.M., 676
 Hayashi, S., 1155
 Haymann, J.-P., E20
 Hebbar, S., 386
 Hebert, L.A., 962

Hébert, M.-J., 1043
 Heimbürger, O., 1212
 Held, P.J., 605
 Helin, H., 343
 Henning, P., 1170
 Heras, M., 488
 Hernández, E., 319
 Herrmann, H.C., 571
 Hida, K., 624
 Hill, G.S., 38
 Hirakata, H., 371
 Hirakawa, M., 371
 Hirano, T., 371
 Hiraoka, M., 1155
 Hishida, A., E10
 Hofmann, A.F., 230
 Hogan, S.L., 455
 Hollander, J.E., 571
 Honda, M., 1110
 Hong, S.Y., E11
 Hons, R., 380
 Hoppel, C., S4:4
 Hörl, W.H., 49
 Hotta, O., 244
 Hsu, C.-y., 162
 Huang, K., 455
 Hueso, M., 1065
 Hurray, C., 1097
 Hussain, N., E17
 Hwang, H.J., 943

Ichikawa, H., 624
 Ieiri, N., 244
 Iglesias, J., 62
 Iida, M., 371
 Iijima, K., 366
 Ikäheimo, R., 1219
 Ikeda, K., 972
 Ikeda, M., 1110
 Ikizler, T.A., 616
 Imam, K., 351
 Inada, T., 833
 Ioannidis, J.P.A., 29
 Isbel, N., 1016, 1170
 Ishihara, K.K., E5
 Isnard-Bagnis, C., 292
 Isozaki, T., E10
 Ito, S.-i., 1110
 Izzedine, H., 292

Jamsheer, A., 709
 Janckila, A.J., 1052
 Janda, K., 203
 Janssen, W. M.T., 733
 Janusz-Grzybowska, E., 203
 Jayne, D.R.W., 776
 Jelacic, S., 709
 Jerums, G., 336
 Jevnikar, A.M., 1140
 Jinde, K., 950
 Johansen, K.L., 162, 171, 447

Johnson, D.W., 1016
 Johnson, J.P., E7
 Johnston, T.D., 464
 Juncos, L.A., 702
 Jung, J.Y., E6

Kainer, G., 1170
 Kakafika, A.I., 1225
 Kaklamani, L., E15
 Kamiyama, M., 637
 Kanai, H., 371
 Kanakiriya, S., 702
 Kang, B.S., 943
 Kang, H.G., 238
 Kang, S.W., 943
 Kapitsinou, P.P., 29
 Kaplan, B.S., 709
 Kaplan, K.L., 471
 Kaplan-Pavlovic, S., 539
 Kasuno, K., 767
 Katafuchi, R., 972
 Kaufman, P., 259
 Kausz, A.T., 76
 Kawamura, S., 1110
 Kazanegra, R., 571
 Kelly, K.J., 1074
 Kerr, P.G., 132, 596
 Keven, K., 1233
 Khan, S., 1060
 Khanna, A., 13
 Khoo, M.S.C., 1247
 Kikuchi, H., 1110
 Kim, D.H., 943
 Kim, G.-H., 1037
 Kim, G.A., 1257
 Kim, H.-J., 1037
 Kim, H.S., E6
 Kim, H.W., E6
 Kim, J., E6
 Kim, M.-J., 1257
 Kim, N., E11
 Kim, N.I., 422
 Kim, S.-G., 1037
 Kim, S.J., 943, E12
 Kim, W.Y., 422
 Kim, Y.O., 422
 Kim, Y.S., E6
 Kimball, K., 13
 Kirwin, P., 105
 Klag, M.J., 149
 Klahr, S., 962
 Klimeczek, P., 203
 Knebelmann, B., 550, E13
 Knight, E.L., 588
 Knudsen, C.W., 571
 Kohno, N., 822
 Koo, J.-R., 1037
 Koomans, H.A., 684
 Korevaar, J.C., 1293
 Kosch, M., 1088
 Koscica, J., 714

Koselj-Kajtna, M., 539
 Kovesi, T., 212
 Kozak, K.R., E5
 Kramer, H.K., 1233
 Kramer, H.M., 588, 643
 Krediet, R.T., 1293
 Krepel, H.P., 807
 Krishnaswamy, P., 571
 Krolewski, A.S., 22, 1189
 Kronenberg, F., 140
 Kubo, M., 371, 972
 Kuboki, T., 833
 Kumano, H., 833
 Kung, W.H., E21
 Kusano, H., 767
 Kutlay, S., 1233
 Kwakye, J., 1327
 Kwon, O., 1074

Laakso, M., 1219
 Labrador, P.J., 488
 Lacson, E. Jr., 111
 Laliberty, P., 442
 Lamba, S., 571
 Lampainen, E., 1219
 Landais, P., 550
 Längle, M., 140
 Langman, C.B., S4:27
 Larson, T.S., 760
 Latos, D.L., 868
 Launay-Vacher, V., 292
 Lazarus, J.M., 111
 Lebon, P., 1205
 Lee, E.-Y., E11
 Lee, E.J., 422
 Lee, H.S., E11
 Lee, H.Y., 943
 Lee, S.-K., 1037
 Lee, S.W., 1257
 Lee, T.H., 943
 Lee, Y.-K., 1037
 Leon, J.B., 125
 León, M., 319
 LePain, N., 1286
 Lerma, J.L., 488
 Lesavre, P., 550, 1205
 Levey, A., 962
 Levey, A.S., 1, 149, 480
 Levin, R., 84
 Levine, J.S., 62
 Levinsky, N.G., 723
 Li, P. K.-T., 250
 Li, R., E21
 Liangos, O., 742
 Lilien, M.R., 684
 Lim, H.J., 1257
 Limcangco, M.R., 849
 Limido, A., 1278
 Lin, Y.-F., 1052
 Lindberg, J., 868
 Lindberg, J.S., S4:1

Lindberg, L.-G., 1026
 Lindholm, B., 1212
 Linossier, M.-T., 558
 Liu, T.C., 692
 Long, E.D., E1
 Lopes, A.A., 605
 Lowrie, E.G., 1286
 Lucas, B.A., 464
 Lucas, M.F., 814
 Lumiaho, A., 1219
 Lunghi, G., 1278
 MacCluer, J.W., 1195
 Macdougall, I.C., 49
 MacKinnon, M., E17
 MacLean, D., 493
 Mac-Moune Lai, F., 250
 Madore, F., 1043
 Magnusson, M., 1026
 Magrini, U., 95
 Mahnensmith, R., 105
 Maisel, A.S., 571
 Makino, H., 624
 Makita, Y., 1189
 Mangano, S., 1278
 Manley, H.J., 386
 Manno, C., 1129
 Manns, B., 380
 Mapes, D.L., 605
 Marboe, C., 891
 Marcén, R., 814
 Mardirossian, S., 225
 Marik, P.E., 62
 Markowitz, G.S., 259, 714, 891
 Martin, A.A., 149
 Martinez, F., 1205
 Marwick, T.H., 1016
 Masse, M., 1043
 Massella, L., 1314
 Masuda, M., 366
 Masutani, K., 371, 972
 Matsubara, K., 1155
 Matsumori, A., 767
 Matsushita, K., 637
 Matsuyama, N., 833
 Matthys, E.G., 877
 Mayumi, M., 1155
 Mbonu, C.C., E14
 McAfee, N., 984
 McCann, L.M., 1008
 McClaran, M.L., 386
 McClellan, W.M., 903
 McCord, J., 571
 McCullough, K., 605
 McCullough, P.A., 571
 McGowan, T., 903
 McKeown, J.W., 464
 McLaughlin, K., 380
 McQuade, M., E16
 Melikian, N., 1322
 Mercanoglu, F., 616
 Mesnard, L., E20
 Meyer, K.B., 149
 Meyrier, A., 38
 Michael, B., 651
 Michael, R., 493
 Miettinen, R., 1219
 Mikami, Y., 637
 Milam, R.A., 433
 Milford, E.L., 411
 Miller, B., S4:44
 Miller, F.J., 508
 Miskulin, D.C., 149, 480
 Miyake, K., 371
 Mizumasa, T., 972
 Moczulski, D.K., 1189
 Modai, D., 196
 Molitoris, B.A., 1074
 Mon, C., E9
 Montseny, J.-J., 38
 Moody, H., 658
 Morales, E., 319
 Moresco, F., 1065
 Morgenstern, B.Z., 760
 Morikawa, Y., 1110
 Mormoi, T., 1155
 Mortis, G., 380
 Moss, A.H., 723
 Moutsopoulos, H.M., 29
 Mulhearn, J., 1247
 Mullins, C.D., 849
 Mündle, M., 140
 Murer, L., 1314
 Muso, E., 767
 Mustonen, J., 343
 Muther, R.S., 386
 Myers, D.I., 351
 Myrski, P., 651
 Myllymäki, J., 343
 Nadasdy, T.A., 471
 Nagake, Y., 624
 Nahashima, H., 371
 Nakanishi, K., 366
 Nakao, K., 624
 Nakopoulou, L., 29
 Nandagopal, R., 76
 Nangaku, M., 833
 Napodano, P., 328
 Narva, A.S., 1195
 Nasr, S.H., 259
 Nasr, S.H., 714, 891
 Nath, K.A., 702
 Navis, G., 733
 Necchi, V., 95
 Neild, G.H., 776
 Neimark, S., 230
 Nelson, D., 742
 Nergizoglu, G., 1233
 Neri, T.M., 1314
 Nette, R.W., 807
 Neufeld, T.K., 386
 Neyer, U., 140
 Ng, D.P.K., 22
 Nguyen, S.T., 220
 Niauet, P., 550
 Nickeleit, V., 696
 Nicol, D.L., 676
 Niemutukia, L., 1219
 Nishi, T., 833
 Noël, L.-H., 532, 1205
 Nogaki, F., 767
 Noh, J.-W., 1037
 Noris, P., 95
 Nowak, R.M., 571
 O'Brien, W.A., 279
 Oflaz, H., 616
 Ofsthun, N., 111
 Oh, K.-H., 1037
 O'Hare, A.M., 162, 447
 Ohashi, N., E10
 Ohi, H., 179
 Ohshima, Y., 1155
 Ohta, K., 1155
 Okada, N., 179
 Okamoto, A., 624
 Omland, T., 571
 Ono, T., 767
 Op't Roodt, J., 684
 Orte, L., 814
 Ortuño, J., 814
 O'Shea, M., 1247
 Osicka, T.M., 336
 Ota, K., 624
 Otsuka, T., 371
 Overbay, D.K., 386
 Owen, S., 1247
 Oyen, W.J.G., E22
 Paganini, E.P., 742
 Pagliari, B., 1278
 Paine, S., 1195
 Palaniappan, L., 580
 Palle, S., 558
 Pancrudo, J., 259
 Paparella, M., 328
 Papo, T., 1205
 Park, H.S., 943
 Park, J.C., 943
 Parker, K.P., 394
 Pasadakis, P., 360
 Pasowicz, M., 203
 Pasternack, A., 343
 Pastural, M., E20
 Paulson, W.D., 518
 Pauly, D.F., S4:35
 Pecci, A., 95
 Pecoits-Filho, R., 1212
 Peel, R., E1
 Pepine, C.J., S4:35
 Perez, A., 571
 Perfumo, F., 1314

Persu, A., E8
 Pesavento, T.E., E19
 Pescovitz, M., 1074
 Petrini, C., 328
 Piedmonte, M.R., 742
 Pierratos, A., 403, E12
 Piette, J.-C., 1205
 Pifer, T., 605
 Pihlajamäki, J., 1219
 Pinto-Sietsman, S.-J., 733
 Piraino, B., 664
 Pirson, Y., E8
 Pisano, L., 328
 Plaisance, M., 776
 Poldermans, D., 807
 Polenakovic, M.H., 997
 Polhinghorne, K.R., 132
 Ponticelli, C., 1278
 Poole, L.J., 351
 Port, F.K., 605
 Porter, J.L., 230
 Powe, N.R., 149, 505
 Pradel, F.G., 849
 Praga, M., 319
 Presne, C., 550
 Preston, R.A., E18
 Pritsivelis, N., 1225
 Prowant, B., 840
 Pusey, C.D., 776
 Pusuroglu, H., 616

Quereda, C., 814
 Quoidbach, A., E8

Rabenou, R.A., 220
 Rahn, K.-H., 1088
 Ramalakshmi, S., E7
 Ramsay, H.M., 676
 Rana, K., 1170
 Rangan, A., 658
 Ranjan, D., 464
 Ravazzolo, R., 95
 Raynaud, A., E20
 Reddy, K.S., 464
 Reid, G.M., 386
 Reisman, J., 212
 Remuzzi, G., E4
 Renwick, N., 891
 Reynolds, J.C., 796
 Richardson, R.M.A., 225
 Rizza, V., 328
 Rizzoni, G., 1314
 Rocco, M.V., 840
 Rodrigues-Neto, J., 186
 Rollino, C., xlvii
 Romagnoli, R., 95
 Ron, Y., E2
 Rosenber, I.H., 480
 Rosenberg, R., 196
 Rossert, J., 49
 Rossetti, S., 90

Roth, D., E18
 Rott, T., 539
 Rousou, J., 1247
 Rozman, B., 539
 Rubel, J.R., 411
 Ruggenenti, P., E4
 Rutkowski, B., 49
 Rye, D.B., 394

Saha, H., 343
 Sakai, H., 950
 Sakhlas, G.K., 171
 Salahudeen, A.K., 925
 Salpigidis, K., E15
 Sánchez, R., E9
 Sandrini, S., 1314
 Santa, C.A., 230
 Santostefano, M., E4
 Sarnak, M.J., S5:11
 Sarris, E., E15
 Sartore, S., 95
 Satayathum, S., 605
 Savige, J., 1170
 Savoia, A., 95
 Scavini, M., 1195
 Schaefer, R.M., 1088
 Schatell, D., 1286
 Scheel, P.J., 351
 Schena, F.P., 1129
 Schoolwerth, A.C., 903
 Schröder, C.H., 684
 Schurgers, M.S., 877
 Schwimmer, J., 471
 Scolari, F., 1314
 Scott, K.M., E16
 Sedlacek, M., 429
 Segal, M., 162
 Sehgal, A.R., 125
 Self, S.E., 1097
 Selhub, J., 442
 Sellars, L., E1
 Senior, H., 670
 Seo, Y.S., E11
 Serferiadis, K.I., 1225
 Seri, M., 95
 Serón, D., 1065
 Sessa, A., 95
 Sesso, R., 186
 Sever, M.S., 616
 Shaer, A.J., 1097
 Shah, S., E5
 Shah, V.O., 1195
 Shanske, S., 259
 Shaw, L., 212
 Shemin, D., 442
 Sherman, D.S., 269
 Shimoyama, H., 833
 Shome, D.K., 709
 Shubert, T., 171
 Shulman, G., E5

Siakotos, M., E15
 Simon, G.L., E14
 Singh, A., 643, 1240
 Singh, U., 1163
 Sirois, I., 1043
 Sivridis, E., 360
 Slezak, J., 90
 Smetana, S., E2
 Smiles, A.M., 1189
 Somers, M.J.G., 984
 Son, B.-K., 1037
 Song, B.-S., 933
 Song, H.C., 422
 Song, J.H., 1257
 Soo, Y.O.-Y., 250
 Sorin, V., E2
 Sotsiou, F., 29
 Spasovski, G.B., 997
 Spitalnik, P.F., 471
 Srivastava, A., 1163
 St. Peter, W.L., 903
 Stablein, D., 464
 Stack, A.G., 310
 Staffeld-Coit, C., 1116
 Stavrianaki, D., E15
 Stefoni, S., 1303
 Steg, P.G., 571
 Stenvinkel, P., 1212
 Stewart, L.R., 1097
 Stidley, C.A., 1195
 Stokes, M.B., 220, 1327
 Stompór, T., 203
 Storrow, A.B., 571
 Stratta, R.J., 464
 Striker, L., E18
 Strippoli, G.F.M., 1129
 Stroes, E.S., 684
 Sudo, S., 179
 Suganuma, N., 1155
 Sugiura, T., E10
 Suliman, M., 1212
 Sulowicz, W., 203
 Suwelack, B., 1088
 Symons, J.M., 984
 Szabo, T., E12
 Szeto, C.-C., 250

Tabernero, J.M., 488
 Tagumna, Y., 244
 Takai, J., 833
 Takata, A., 1110
 Takeda, M., 637
 Takeda, N., 1155
 Tam, V.K.K., E21
 Tamano, M., 179
 Tan, L.K., 692
 Tanaka, H., 972
 Tanaka, J., 822
 Taranto, S., 464
 Tarr, P.I., 709
 Taub, K., 380

Taupin, P., 550
 Tawney, K., 447
 Taylor, A.J., 1267
 Taylor, J., 493
 Teitelbaum, I., 269
 Tentori, F., 1195
 Teodorescu, V., 429
 Termorshuizen, F., 1293
 Terrado, L.T., E19
 Teruel, J.L., 814
 Tettamanzi, F., 1278
 Thakar, C.V., 742
 Thaker, H.M., 891
 The, T.H., 859
 Therby, A., E13
 Thi, T.X.N., 220
 Thomas, S., 523
 Togawa, A., E10
 Torras, J., 1065
 Torres, V.E., 90
 Touam, M., E13
 Touchard, G., 497
 Toulopidis, S., 360
 Tracz, W., 203
 Trespalacios, F.C., 796, 1267
 Troyanov, S., 1043
 Tsele, E., E15
 Tsianos, E.V., 1225
 Tsukahara, H., 1155
 Tsurusawa, M., 1155
 Tsuruya, K., 371
 Tuttle, K.R., 76
 Uhlin, F., 1026
 Uribarri, J., 429
 Valderrábano, F., 49
 Valero, M.A., 319
 van den Dorpel, M.A., 807
 van den Meiracker, A.H., 807
 van der Heide, J.J.H., 859
 van der Woude, F.J., 532
 van Gurp, E., 532
 van Hamersveld, H.W., E22
 Van Hoof, V.O., 997
 van Houwelingen, H.C., 532
 van Manen, J.G., 1293
 van Son, W.J., 859
 Vargemezis, V., 360
 Vergunst, C.E., 532
 Vienken, J., 1303
 Vigneault, N., 1043
 Vizjak, A., 539
 Wada, J., 624
 Waid, T.H., 464
 Wai-Kei Lam, C., 250
 Waldherr, R., 532
 Walker, D., 90
 Wang, Q., 664
 Warnock, D.G., 651
 Warram, J.H., 22, 1189
 Watanabe, H., 767
 Watnick, S., 105
 Wauters, J.P., 49
 Weber, M.L., xli
 Weimar, W., 807
 Weissgarten, J., 196
 Wells, H., 493
 Welty, T.K., 1195
 Wesson, D.E., 13
 Westheim, A., 571
 Wilmer, W.A., E19
 Wilson, D.M., 760
 Winearls, C.G., 90
 Winkelmayr, W.C., 84
 Wish, J.B., 254
 Wójcik, K., 203
 Wolfe, R.A., 605
 Wollan, P., 760
 Worrall, N.K., 76
 Wright, M.A., 386
 Wrone, E.M., 580, 1008
 Wu, A.H.B., 571
 Wu, Q., 950
 Xuan, B.H.N., 220
 Yakubovich, M., 1303
 Yam, L.T., 1052
 Yamagata, Z., 637
 Yamamoto, T., E10
 Yanase, T., 972
 Yang, C.W., 422, E6
 Yang, J.O., E11
 Yared, J.-P., 742
 Yildiz, A., 616
 Yodoi, J., 767
 Yonemura, K., E10
 Yoon, J.-W., 1037
 Yoon, S.A., 422
 Yorioka, N., 822
 Yoshikawa, N., 366
 Yoshizawa, N., 366
 Young, E.W., 605
 Yussim, A., 1303
 Zafirovska, K., 997
 Zager, P.G., 1195
 Zaman, F., 518
 Zand, M.S., 471
 Zdienicka, A., 203
 Zietse, R., 807
 Zimmet, P.Z., 596
 Zuber, J., E13, 1205

SUBJECT INDEX

Articles appearing on AJKD ELECTRONIC PAGES are referred to by journal number, a colon, the letter E and a number.

Page references to Supplement 1 (March 2003), Supplement 2 (April 2003), Supplement 3 (April 2003), Supplement 4 (April 2003), and Supplement 5 (June 2003) are preceded, respectively, by S1:, S2:, S3:, S4:, and S5:.

Abdominal aortic aneurysm, causing obstructive acute renal failure, E9
N-Acetylcysteine (NAC), homocysteine levels in hemodialysis and, 442–446
 Acidosis, in drug-induced Fanconi syndrome, 292–309
 ACR. *See* Albumin-creatinine ratio
 Actin, urinary, ARF prediction after ischemic injury in allografts, 1074–1087
 Acute interstitial nephritis (AIN)
 drug-induced, in allograft dysfunction, 1116–1121
 zopiclone-induced, E17
 Acute renal failure (ARF)
 after accidental perchloroethylene ingestion, E11
 after fish gallbladder ingestion, 220–224
 after open-heart surgery, 724–751
 in antiphospholipid syndrome, 1205–1211

with backache, E1
caused by inflammatory abdominal aortic aneurysm, E9
caused by renal parenchymal malacoplakia, E21
infantile, CRRT for, 984-989
with nephrotic syndrome in diabetes mellitus, 1327-1333
post-renal transplant thrombotic microangiopathy and, 471-479
prediction after ischemic injury in allografts, 1074-1087
with radical nephrectomy-associated rhabdomyolysis, E5
in septic shock, proinflammatory cytokines and, 62-75
Acute tubular necrosis (ATN)
after fish gallbladder ingestion, 220-224
pamidronate-induced, E18
Acyclovir nucleoside phosphonates, Fanconi syndrome induction and, 292-309
Adefovir, Fanconi syndrome induction and, 292-309
Adenovirus infection, of renal allograft, 696-701
Adequacy
hemodialysis
comparison of database URR and hematocrit values, 433-441
daily, S1:112-115
dual dialyzers in parallel and series comparisons, 1008-1015
peritoneal dialysis, prescription changes and, 840-848
Adjuvant vitamin C, effect on EPO response in hemodialysis, 1233-1239
Adolescent dyslipidemia, treatment of, S3:56-58
ADPKD. *See* Autosomal dominant polycystic kidney disease
Advanced glycation end product inhibitors
development of, S1:42-47
progression of nephropathy and, S1:68-71
Advanced glycation end products (AGEs)
cardiovascular risk in CRF and, S1:52-56
dietary, effect on rat remnant kidney model, S1:48-51
formation during CAPD, S1:57-60
nephrotoxicity, new therapies for, S1:42-47
peritoneal dysfunction in CAPD and, S1:61-67
Adynamic bone disease, diagnostic markers in predialysis ESRD patients, 997-1007
Age
left ventricular dysfunction in ESRD and, 1016-1025
prevalence of peripheral arterial calcification in ESRD and, 140-148
AGES. *See* Advanced glycation end products
AIN. *See* Acute interstitial nephritis
Albumin, hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89-95
Albumin-creatinine ratio (ACR)
diabetic nephropathy progression and, 13-21
protein intake in healthy adults and, 580-587
Albuminuria. *See also* Microalbuminuria
immuno-unreactive, in diabetes mellitus, 336-342
kidney function in US population and, 1-12
in predicting diabetic nephropathy progression, 13-21
Allograft
adenovirus infection, 696-701
chronic nephropathy
in aging kidney, cyclin-dependent kinase inhibitor genes and, 1303-1313
with repeated rejections and tubular renal acidosis, E6
dysfunction
drug-induced AIN in, 1116-1121
insulin resistance and, 859-867
ischemic injury, ARF prediction after, 1074-1087
rejection
control, low-protein intake for, S1:146-152
endothelium growth phenotype and, 1140-1154
stable, structural and functional correlations in, 1065-1073
Alopecia, in hemodialysis patient caused by tinzaparin, E15
Alport-like syndrome
basement membrane changes in Frasier syndrome, 1110-1115
nonmuscle myosin IIA abnormality in, 95-104
Amino acid score, low-protein diet for very late stage CRF, S1:31-34
Aminoglycosides
Fanconi syndrome induction and, 292-309
for peritonitis, residual renal function unaltered by, 670-675
Amputation risk factors, in hemodialysis, 162-170
Anaphylactoid-type reactions, from iron therapy, S5:18-25
ANCA-associated disorders
glomerulonephritis
histologic and immunohistologic study of, 539-549
index for renal outcome in, 532-538
ANCA-associated-disorders
renal vasculitis, 5-year retrospective study, 776-784
Anemia
comparison of database URR and hematocrit values, 433-441
effect of hemoglobin variability on management, 111-124
endothelial dysfunction and LVH in chronic hemodialysis, 616-623
erythropoietin therapy, vitamin C and, 1233-1239
in ESRD with HIV infection, 279-291
high-dose sodium ferric gluconate complex for, 651-657
levocarnitine for, 868-876, S1:116-122, S4:27-34
predialysis survey on, 49-61
promotion of cardiovascular disease in CKD, S5:11-17
rHuEPO hyporesponsive patients
CD34+ cells in, 624-636
levocarnitine for, S4:27-34
rHuEPO therapy mechanisms, 179-185
Angina, levocarnitine therapy for, S4:35-43
Angiomyolipoma, pulmonary lymphangioleiomyomatosis and, 877-883
Angioplasty, delayed after renal thrombosis, E20
Angiotensin-converting enzyme gene polymorphisms, diabetic nephropathy progression, 943-949
Angiotensin-converting enzyme inhibitors
diabetic nephropathy progression, albuminuria and, 13-21
under usage in chronic dialysis of heart failure patients, 1267-1277
Angiotensin II, CKD progression and, S1:3-7
Anticancer drugs, Fanconi syndrome induction and, 292-309

Anticardiolipin antibodies, in antiphospholipid syndrome, 1205–1211

Anticonvulsants, Fanconi syndrome induction and, 292–309

Anti-DNA antibodies, in antiphospholipid syndrome, 1205–1211

Antigen-presenting cells, in crescentic glomerulonephritis, 950–961

Antiglomerular basement membrane nephritis, Crohn's disease and, 1097–1109

Antineutrophil cytoplasmic antibody associated -associated disorders. *See* ANCA-associated disorders

Antioxidants, carnitine supplementation in hemodialysis and, S1:116–122

Antiphospholipid antibodies, renal diseases associated with, 1205–1211

Antiphospholipid syndrome, renal diseases associated with, 1205–1211

Antiretroviral therapy, in ESRD with HIV infection, 279–291

Antistreptolysin O, in Henoch-Schönlein nephritis, 366–370

Antiviral agents, Fanconi syndrome induction and, 292–309

Anxiety, restless legs syndrome in uremic hemodialysis, 833–839

Aortic valve replacement, predictors of ARF after, 76–83

Apolipoprotein E
gene polymorphism, carotid atherosclerosis and, 822–832
in lipoprotein glomerulopathy, lipid-lowering therapy for, 244–249

Apoptosis
endothelial cell, allograft function and, 1140–1154
soluble Fas as predictor of atherosclerosis in ESRD, 1043–1051

Apoptosis inhibitors, allograft survival and, 1140–1154

ARF. *See* Acute renal failure

Arterial distensibility, fluvastatin effects on hypercholesterolemic renal transplant recipients, 1088–1096

Arterial stiffness, in pediatric renal transplant recipients, 684–691

Arteriovenous fistula
blood flow and resistance during hemodialysis, 132–139
thrombosis risk, MTHFR gene polymorphism and, 637–642
vasculature in women and, 429–432

Asian traditional medicine, ichthyotoxic acute renal failure from, 220–224

Aspergillosis graft infection, after cadaveric renal transplant, 488–492

AST-120
effect on tryptophan metabolism in uremia, S1:38–41
gene expression in uremic kidney and, S1:8–14
with low-protein diet, effect on creatinine slope in CRF, S1:35–37

Atherosclerosis
apoE polymorphism and, 822–832
with diabetic nephropathy, renal artery stenosis in, 351–359
in ESRD
intima-media thickness of carotid artery and, S1:76–79
peritoneal dialysis, chronic inflammation and, 203–211
prevalence of peripheral arterial calcifications, 140–148
soluble Fas as predictor of, 1043–1051

iron in, S1:80–83
renal transplant, insulin resistance and, 859–867

ATN. *See* Acute tubular necrosis

Atorvastatin, effect on proteinuria and progression of kidney disease, 565–570

Atovaquone, for PCP in non-HIV hemodialyzed patient, E13

ATP6B1 gene mutations, distal renal tubular acidosis and deafness in child and, 238–243

Australia
health-related quality of life in ESRD, 596–604
post-renal transplant prediction of nonmelanoma skin cancer, 676–683

Autosomal dominant polycystic kidney disease (ADPKD)
D298 ENOS polymorphism in, 90–94
diagnosis of renal and hepatic cysts by 18-FDG-PET, E22
multiple thoracic paraspinal meningeal cysts in, E8
type 1, insulin resistance and left ventricular hypertrophy in, 1219–1224

Autosomal recessive distal renal tubular acidosis, ATP6B1 gene mutations in, 238–243

Backache, with renal failure, E1

Basement membrane, Alport syndrome-like changes in Frasier syndrome, 1110–1115

Beck Depression Inventory, for new dialysis patients, 105–110

Bence Jones Vκ light chain, in myeloma tubulopathy, 497–504

Best practice guidelines, for anemia management, 49–61

Beta-blockers, under usage in chronic dialysis, 1267–1277

Bifidobacterium, indoxyl sulfate levels in hemodialysis and, S1:142–145

Bile acid replacement therapy, for short bowel syndrome, 230–237

Bile acid sequestrants, for lipid lowering in kidney transplant recipients, S3:52–53

Biochemical markers, of renal osteodystrophy in predialysis ESRD patients, 997–1007

Bisphosphonate nephrotoxicity, mechanisms of, E18

Blood pressure
arteriovenous fistula blood flow during hemodialysis, 132–139
elevated. *See* Hypertension
high-normal, microalbuminuria and, 588–595
reduction, effect on albuminuria and diabetic nephropathy progression, 13–21

BMI. *See* Body mass index

BNP. *See* Brain natriuretic peptide

Body fat mass
central distribution relationship to renal function impairment, 733–741
in hemodialysis patients, S1:137–141

Body mass index (BMI)
survival on dialysis and, 925–932
at time of renal transplantation, 480–487

Bone alkaline phosphatase, renal osteodystrophy in predialysis ESRD patients, 997–1007

Bone histomorphometry, of uremic patients on maintenance HD, 1052–1059

Bone mineral density (BMD)
in children with idiopathic nephrotic syndrome, 1163–1169
in postmenopausal hemodialysis-dependent women, 1240–1246

Bouï-Ougi-Tou, Fanconi syndrome and, 292–309

Brain natriuretic peptide (BNP)
assessment of hydration status in hemodialysis, 1257–1266
and renal function in heart disease diagnosis, 571–579

Breathing Not Properly Multinational Study, BNP and renal function in heart failure diagnosis, 571–579

Bronchoalveolar lavage, EBV load determination in children, 212–219

Calcimimetics
for secondary hyperparathyroidism, S1:100–103
with vitamin D analogues, for secondary hyperparathyroidism, S1:104–107

Calcineurin-inhibitor-based immunosuppression, thrombotic microangiopathy after, 471–479

Calcinosis, daily home hemodialysis for, E12

Calcitriol analogue, for secondary hyperparathyroidism, S1:100–103

Calcium
in cardiac valvular disease in hemodialysis patients, 411–421
cytosolic, in hepatocytes in CRF, S1:127–132
in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997–1007
metabolic alterations, promotion of cardiovascular disease in CKD, S5:11–17
in secondary hyperparathyroidism, calcimimetics in, S1:104–107

Calcium phosphate control, nocturnal hemodialysis for peripheral arterial disease, 225–229

Caloric intake, oral nutritional supplementation for PD, 658–663

CAPD. *See* Continuous ambulatory peritoneal dialysis

Carbohydrate metabolism, in liver of chronic renal failure patient, S1:127–132

Carbon absorbent, oral. *See* Oral absorbent

Carboplatin, Fanconi syndrome induction and, 292–309

Nε-(Carboxymethyl)lysine (CML)
accumulation in glomerular lesions, AGE inhibitor and, S1:68–71
cardiovascular risk and, S1:52–56
formation during CAPD, S1:57–60

Cardiac calcification in hemodialysis, calcium-phosphate imbalance and, 411–421

Cardiac surgery
predictors of ARF after, 76–83
for valvular disease, calcium-phosphate imbalance and, 411–421

Cardiomyopathy
congestive, carnitine supplementation for, S4:4–12
in dialysis-related carnitine disorder, 868–876, S4:13–26
in ESRD, levocarnitine therapy for, S4:35–43

Cardiopulmonary bypass
bleeding complications, chronic kidney disease and, 84–89
during hemodialysis, outcome/complications of, 1247–1256

predictors of ARF after, 76–83

Cardiovascular disease (CVD)
atherosclerotic, dyslipidemia and, S3:22–24
in ESRD, hyperhomocysteine and, S1:89–95
heart failure as cause for hospitalization in chronic dialysis patients, 1267–1277

homocysteine in uremia and, S1:123–126
morbidity in hemodialysis, *N*-acetylcysteine effect on homocysteine and, 442–446

mortality in hemodialysis
hypertension and, 814–821
intima-media thickness of carotid artery and, S1:76–79
vascular calcifications and, S1:96–99

prediction, soluble Fas and, 1043–1051

risk, iron therapy and, S5:18–25

treating complications in chronic kidney disease, S5:11–17

valvular, calcium-phosphate imbalance in HD and, 411–421

Carnitine. *See also* Levocarnitine
in fatty acid metabolism, S4:4–12
supplementation, for hemodialysis, S1:116–122
in understanding dialysis-related disorders, S4:1–3

Carotid atherosclerosis, apoE polymorphism, eNOS polymorphism and, 822–832

Case-mix factors, influence on incident dialysis patient survival, 149–161

Caspases, regulation of apoptosis, allograft rejection and, 1140–1154

CD59 erythrocyte expression, rEPO and, 179–185

CD80, in crescentic glomerulonephritis, 950–961

CD86, in crescentic glomerulonephritis, 950–961

Cell-surface molecules, in crescentic glomerulonephritis, 950–961

Centers for Medicare & Medicaid Services, URR and hematocrit values compared with different data systems, 433–441

Central venous pressure, dialysis-related hypotension and, 807–813

Chemokine receptors, in progressive renal diseases, S1:15–18

Chemokines, in progressive renal diseases, S1:15–18

CHF. *See* Congestive heart failure

Children
ATP6B1 gene mutations in autosomal recessive distal renal tubular acidosis, 238–243
estimating proteinuria in, 760–766
with Henoch-Schönlein nephritis, group A streptococcal antigen in, 366–370
with idiopathic nephrotic syndrome, metabolic bone disease and, 1163–1169
infants, continuous renal replacement therapy for, 984–989
with lupus nephritis, renal transplantation for, 455–463
with nephrotic syndrome, long-course prednisolone for, 155–1162
organ transplant recipients
acute myelomonocytic infiltrate in lower esophagus, E16
quantitative EBV-tissue PCR in, 212–219
vascular function in, 684–691

steroid-sensitive nephrotic syndrome, long-term complications, 550–557

Choices for Healthy Outcomes in Caring for End-Stage Renal Disease Cohort Study, prognostic importance of comorbidity, 149–161

Cholesterol

- intermediate-density, as target for lipid-lowering therapy in dialysis patients, S1:72–75
- low-density. *See* Low-density lipoprotein
- non-HDL, treating in patients with high triglycerides, S3: 53–56

Chronic kidney disease (CKD)

- ambulatory GFR measurement with cold iothalamate, 752–759
- bleeding complications after coronary artery bypass surgery and, 84–89
- cardiovascular complications in, S5:11–17
- carnitine supplementation, S4:4–12
- with dyslipidemia, therapeutic lifestyle changes for, S3: 68–70
- establishing programs to improve patient outcomes, 903–924
- K/DOQI Outcome Quality Initiative guidelines and, S5: 3–10
- obesity at time of renal transplantation and, 480–487
- prevalence, 1–12
- prevention, early referral and, 505–507
- progression, S1:3–7

Chronic renal failure (CRF). *See also* End-stage renal disease

- carnitine supplementation, S4:4–12
- chemokines and chemokine receptors in, S1:15–18
- daytime sleepiness in, 403–410
- dialysis-related carnitine disorder in, S13–26
- homocysteine in, S1:123–126
- liver metabolism in, S1:127–132
- patient functionality on maintenance HD, levocarnitine and, S4:44–48
- quality of life, socioeconomic status and, 186–195
- reciprocal creatinine slope, effects of low-protein diet with oral carbon adsorbent, S1:35–37
- residual renal function, circulating inflammatory markers and, 1212–1218
- rHuEPO-hyporesponsive hemodialysis patients, CD34+ cells in, 624–636
- with rHuEPO hyporesponsiveness, levocarnitine for, S4: 27–34
- risk, advanced glycation end products and, S1:52–56
- secondary hyperparathyroidism, new treatment strategies for, S1:100–103
- tryptophan metabolism, effect of oral adsorbent on, S1: 38–41
- very late stage, low-protein diet for, S1:31–34

Churg-Strauss angiitis, 5-year retrospective study, 776–784

Cidofovir, Fanconi syndrome induction and, 292–309

Cirrhotic patients, assessing renal function in, 269–278

Cisplatin, Fanconi syndrome induction and, 292–309

CKD. *See* Chronic kidney disease

Clostridium difficile colitis, with hemolytic uremic syndrome, E14

CML. *See* Nε-(Carboxymethyl)lysine

C₂ monitoring of drug interaction, in renal transplant patient, 493–496

Cochrane Renal Group Report

- December 2002 ongoing trials, 884–890
- published trials, 884–890

Cockcroft-Gault equation, in chronic kidney disease prediction, 1–12

Comorbidity

- in chronic kidney disease, outcome improvement for, 903–924
- influence on incident dialysis patient survival, 149–161
- medication-related problems in ambulatory hemodialysis and, 386–393
- prognostic importance in chronic dialysis, 149–161

Complementary DNA array, AST-120 effects on gene expression in uremia, S1:8–14

Complement receptor 1, rHuEPO treatment and, 179–185

Complement regulatory proteins, rHuEPO and, 179–185

Congenital anomalies, with von Hippel-Lindau gene mutation and bilateral pheochromocytomas, E3

Congestive heart failure (CHF)

- diagnosis, BNP and renal function in, 571–579
- levocarnitine therapy for, S4:35–43

Conjugated bile acid replacement therapy, for short bowel syndrome, 230–237

Continuous ambulatory peritoneal dialysis (CAPD)

- advanced glycation end product formation during, S1: 57–60
- culture-negative peritonitis, pancreaticoduodenectomy leak of pancreas transplant and, E19
- peritoneal dysfunction, role of growth factors and AGEs in, S1:61–67
- secondary fecal incontinence, E2

Continuous renal replacement therapy (CRRT), for infants, 984–989

Continuous venovenous hemodiafiltration, and hemodialysis for iodine toxicity, 702–708

Coronary artery bypass graft. *See* Cardiopulmonary bypass

Coronary artery calcification, chronic inflammation in peritoneal dialysis for ESRD, 203–211

Corticosteroid toxicity, in long-course prednisolone regimens for children with nephrotic syndrome, 1155–1162

C-reactive protein, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Creatine, in cirrhotic patients, 269–278

Creatinine

- in cirrhotic patients, 269–278
- in CRF, effects of low-protein diet with oral carbon adsorbent on, S1:35–37
- diabetic nephropathy progression and, 13–21
- outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Creatinine clearance

- in antiphospholipid syndrome, 1205–1211
- in cirrhotic patients, 269–278
- improvement after PD prescription change, 840–848
- in US population, 1–12

Crescentic glomerulonephritis

- CD80 and CD86 in, 950–961
- stem cell factor and, 785–795

Crohn's disease, IgA antiglomerular basement membrane nephritis and, 1097–1109

CRRT (continuous renal replacement therapy), for infants, 984–989

Cryoglobulinemia, antiglomerular basement membrane nephritis with Crohn's disease and, 1097–1109

CVD. *See* Cardiovascular disease

Cyclin-dependent kinase inhibitor genes, in aging kidney and chronic allograft nephropathy, 1303–1313

Cyclosporine

- interaction with Orlistat in renal transplant patient, 493–496
- for post-rHuEPO pure red blood cell aplasia, 692–695
- thrombotic microangiopathy after renal transplant and, 471–479

Cytokines. *See also* specific cytokines

- chronic inflammation in ESRD PD patients and, 203–211
- circulating levels, residual renal function in CRF and, 1212–1218
- proinflammatory, acute renal failure of septic shock and, 62–75

Cytotoxic agents, for proteinuria in IgA nephropathy, 1129–1139

Databases, URR and hematocrit value comparisons, 433–441

Daytime sleepiness. *See* Sleepiness, daytime

ddI, Fanconi syndrome induction and, 292–309

Decay accelerating factor, rHuEPO and, 179–185

3-Deoxyglucosone

- cardiovascular risk and, S1:52–56
- formation during CAPD, S1:57–60

Depression

- and malnutrition in chronic hemodialysis patients, 1037–1042
- in new dialysis patients, 105–110
- treatment, for new dialysis patients, 105–110

Diabetes mellitus. *See also* Diabetic nephropathy

- acute muscle infarction in dialysis patients, 1322–1326
- acute renal failure with nephrotic syndrome in, 1327–1333
- amputation risk for hemodialysis patients, 162–170
- care, provision and outcome in hemodialysis patients, 125–131
- in chronic kidney disease prediction, 1–12
- chronic renal transplant dysfunction risk and, 859–867
- with ESRD, assessing glycemic control in, 523–531
- hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89–95
- with hypertension, protein intake, microalbuminuria and, 580–587
- hypouricemia in inpatient hospital-based facility, 1225–1232
- immuno-unreactive albumin in urine, 336–342
- left ventricular dysfunction in ESRD and, 1016–1025
- prevalence of peripheral arterial calcification in ESRD and, 140–148
- protein intake, microalbuminuria and, 580–587
- type I

 - long-term survival after kidney-pancreas transplant, 464–470
 - susceptibility to diabetic nephropathy, 1189–1194

type 2

- drug interaction in renal transplant patient, 493–496
- interrelated predictors of progression in, 13–21
- recent management advances, S1:22–25
- weight loss for overweight chronic proteinuric nephropathy, 319–327

Diabetic nephropathy

- AGE nephrotoxicity, new therapies for, S1:42–47
- effect of oral adsorbent and with low-protein diet on creatinine slope, S1:35–37
- OPB-9195 amelioration of glomerular lesions in, S1:68–71
- progression, S1:19–21
- ACE gene polymorphism and, 943–949
- losartan and, S1:22–25
- smoking and albuminuria as predictors of, 13–21
- susceptibility in type 1 diabetes, MTHFR gene polymorphism and, 1189–1194
- with uncontrolled hypertension, renal artery stenosis in, 351–359

Dialysis. *See also* Hemodialysis; Peritoneal dialysis

- atherosclerosis in, soluble Fas as predictor of, 1043–1051
- carnitine supplementation, S4:4–12
- for diabetic ESRD patients, glycemic control in, 523–531
- exercise counseling by nephrologists, 171–178
- hepatitis B viremia in, determination of viral load in, 1278–1285
- levocarnitine therapy for, S4:4–12
- modality selection, barriers for self-care dialysis in ESRD, 380–385
- monitoring, estimation of delivered dose by UV absorbance, 1026–1036
- new patients, depression in, 105–110
- prevalence of peripheral arterial calcification in ESRD and, 140–148
- survival, obesity and, 925–932

Dialysis dose

- for dialysis patients, protein intake and, S1:133–136
- estimation by UV absorbance, 1026–1036

Dialysis Morbidity and Mortality Study Wave 2

- heart failure as cause for hospitalization in chronic dialysis patients, 1267–1277
- pre-ESRD referral timing and, 310–318
- sedentary behavior effect on dialysis patient survival, 447–454

Dialysis Morbidity and Mortality Study Waves 3 and 4

- amputation risk factors, 162–170
- time of day for hemolysis, survival and, 796–806

Dialysis Outcomes and Practice Patterns Study, health-related quality of life for ESRD hemolysis patients of different ethnicities, 605–615

Dialysis-related carnitine disorder

- L-carnitine for, 868–876
- evolving understanding of, S4:1–3
- levocarnitine pharmacology and, S13–26

Diet. *See also* Nutrition

- low-calorie, for overweight chronic proteinuric nephropathy patients, 319–327
- low-protein. *See* Low-protein diet

DNA hybridization, determination of HBV viral load in dialysis patients, 1278–1285

DNA sequence variants, advanced diabetic nephropathy and, 22–28

Drug interaction, in renal transplant patient, 493–496

Dual dialyzers, comparison in parallel and series, 1008–1015

Dual x-ray absorptiometry, body fat mass in hemodialysis, S1:137–141

Duplex ultrasound of vasculature, gender differences in, 429–432

Dyslipidemia

- assessment, K/DOQI Clinical Practice guidelines for, S3: 22–38
- chronic renal transplant dysfunction risk and, 859–867
- prevalence, S3:26–29
- treatment, K/DOQI Clinical Practice guidelines for, S3: 39–58

EBV (Epstein-Barr virus), quantitative tissue PCR in pediatric solid organ recipients, 212–219

Elderly renovascular disease, blood pressure and renal function in, 990–996

ELISA tissue EBV, for pediatric solid organ recipients, 212–219

Endothelial cells

- fluvastatin effects on hypercholesterolemic renal transplant recipients, 1088–1096
- progenitors, in vessel repair, allograft survival and, 1140–1154
- survival in predicting allograft acceptance/function, 1140–1154

Endothelial dysfunction

- and left ventricular hypertrophy in chronic hemodialysis, 616–623
- in pediatric renal transplant recipients, 684–691

Endothelial nitric oxide synthase gene polymorphism

- carotid atherosclerosis and, 822–832
- in polycystic kidney disease 1, 90–94

Endothelin-1, in uremic kidney, AST-120 effects on, S1: 8–14

Endothelium growth phenotype, allograft survival and, 1140–1154

End-stage renal disease (ESRD)

- anemia, effect of hemoglobin variability in, 111–124
- cardiovascular disease
 - hyperhomocysteinemia in, S1:89–95
 - levocarnitine therapy for, S4:35–43
 - carnitine supplementation, S4:4–12
 - chronic hemodialysis, deselection for, 723–732
 - depression and, 105–110
 - with diabetes, MTHFR gene polymorphism and, 1189–1194
 - diabetic nephropathy progression
 - losartan and, S1:22–25
 - smoking, albuminuria and, 13–21
 - dialysis modality effect on HIV-associated nephropathy survival, 1060–1064
 - dialysis-related carnitine disorder in, S13–26
 - erythropoietin therapy in hemodialysis patients, vitamin C and, 1233–1239
 - health-related quality of life
 - in hemodialysis patients of different ethnicities, 605–615

population-based study of, 596–604

hemodialysis-dependent, early onset menopause and postmenopausal hormone therapy, 643–650

with HIV infection, management of, 279–291

impact of pre-ESRD referral timing, 310–318

intima-media thickness of carotid artery in, S1:76–79

K/DOQI Outcome Quality Initiative guidelines and, S5: 3–10

kidney-pancreas transplant for type 1 diabetes mellitus and, 464–470

maintenance hemodialysis, patient functionality, levocarnitine and, S4:44–48

peripheral arterial calcification in, 140–148

peripheral arterial disease, nocturnal hemodialysis for, 225–229

in PR3-ANCA vasculitis, proinflammatory IL-1 β /il-1ra genotype and, 933–942

quality of life, socioeconomic status and, 186–195

with rHuEPO hyporesponsiveness, levocarnitine for, S4: 27–34

risk factors, in pauci-immune necrotizing glomerulonephritis, 29–37

self-care dialysis, barriers toward, 380–385

subclinical left ventricular dysfunction, risk factors for, 1016–1025

USRDS 2002 Annual Data Report, S2:1–253

vascular calcifications in, S1:96–99

Energy intake, balancing dialysis dose and protein intake for dialysis patients, S1:133–136

Eosinophil-rich interstitial infiltrate, in allograft dysfunction, 1116–1121

Epidemiology, of predialysis patients, retrospective chart review for, 49–61

EPO. *See* Erythropoietin

Epoetin. *See* Erythropoietin

Epstein-Barr virus (EBV), quantitative tissue PCR in pediatric solid organ recipients, 212–219

Erythroid progenitors, in hyporesponsive rHuEPO CRF patients, 624–636

Erythropoietin (EPO)

- effect of hemoglobin variability on, 111–124
- recombinant human. *See* Recombinant human erythropoietin response in hemodialysis patients, vitamin C and, 1233–1239

Escherichia coli O157:H7 bacteremia, nondiarrheal hemolytic uremic syndrome with UTI, E4

ESRD. *See* End-stage renal disease

Estrogen

- early menopause and hormone use in dialysis-dependent women, 643–650
- in postmenopausal hemodialysis-dependent women, 1240–1246

Ethnicity, health-related quality of life for ESRD hemolysis patients, 605–615

Ethyl-icosapentate, in lipid-lowering therapy for lipoprotein glomerulopathy, 244–249

Exercise counseling, by nephrologists, 171–178

Fanconi syndrome

- compared with V κ light chain in myeloma tubulopathy, 497–504

drug-induced, 292–309

Fatty acid metabolism, carnitine in, S4:4–12

Fear, as barrier for self-care dialysis in ESRD, 380–385

Fecal fat excretion, in short bowel syndrome, 230–237

Fecal incontinence, secondary to CAPD, E2

Fechtner syndrome, nonmuscle myosin IIA abnormality in, 95–104

Females

- acute renal failure after open-heart surgery, 724–751
- dialysis-dependent, early onset menopause in, 643–650
- postmenopausal. *See* Postmenopausal women

Fenofibrate, for lipoprotein glomerulopathy, 244–249

Ferritin, prediction of ARF after cardiac surgery and, 76–83

Fish gallbladder ingestion, nephrotoxic, 220–224

Fish oils, for proteinuria in IgA nephropathy, 1129–1139

Flow-mediated dilatation

- endothelial dysfunction and LVH in chronic hemodialysis, 616–623
- in pediatric renal transplant recipients, 684–691

Fluoroquinolones, renal parenchymal malacoplakia causing acute renal failure, E21

18-F-Fluorodeoxyglucose PET, diagnosis of renal and hepatic cysts in ADPKD, E22

Fluvastatin, for hypercholesterolemic renal transplantation recipients, 1088–1096

Focal segmental glomerulosclerosis (FSGS)

- in antiphospholipid syndrome, 1205–1211
- family, clinical, histopathologic and genetic studies of, 1170–1178
- in IgM nephropathy, 343–350
- membranous nephropathy prognosis and, 38–48
- nephronoplastic, glomerular basement membrane length to podocyte ratio, 1179–1188
- outcome prediction, IgG excretion and, 328–335
- recurrence after pediatric renal transplantation, 1314–1321

Frasier syndrome, Alport syndrome-like basement membrane changes in, 1110–1115

Fructosamine, in diabetic ESRD patients, 523–531

FSGS. *See* Focal segmental glomerulosclerosis

Fumaric acid, Fanconi syndrome induction and, 292–309

Functional well-being, in dialysis-related carnitine disorder, 868–876

Galactosylation abnormalities, in IgA nephropathy, 558–564

Gamma-glutamyl transpeptidase (GGTP), prediction of ARF after allograft ischemic injury, 1074–1087

Gene expression, lipogenic, in triglyceride biosynthesis in uremia, S1:84–88

Gene for α -actinin 4 (ACTN4), in focal segmental glomerulosclerosis, 1170–1178

Gene for steroid resistant nephrotic syndrome 2, in FSGS, 1170–1178

Gene mutations, distal renal tubular acidosis and deafness in child and, 238–243

Gene polymorphisms

- carotid atherosclerosis and, 822–832
- diabetic nephropathy and, 22–28
- IgA nephropathy progression and, 371–379
- polycystic kidney disease 1 and, 90–94

Genetic studies, of familial focal segmental glomerulosclerosis, 1170–1178

GFR. *See* Glomerular filtration rate

Glomerular basement membrane

- length in nephropenic FSGS, 1179–1188
- thickness in IgA nephropathy, 558–564

Glomerular filtration rate (GFR)

- ambulatory measurement with cold iothalamate, 752–759
- and BNP in congestive heart failure diagnosis, 571–579
- in chronic kidney disease
- bleeding complications after CABG and, 84–89
- circulating inflammatory markers and, 1212–1218
- prediction, 1–12

in cirrhotic patients, 269–278

decline, high urine volume, low urine osmolality and, 962–971

effects of dietary AGEs on, S1:48–51

K/DOQI Outcome Quality Initiative Guidelines and, S5: 3–10

renal outcome in ANCA-associated glomerulonephritis and, 532–538

Glomeruli, abnormal, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Glomerulonephritis

- ANCA-associated, index for renal outcome in, 532–538
- chronic, effect of oral adsorbent and with low-protein diet on creatinine slope, S1:35–37
- inherited, nonmuscle myosin IIA abnormality in, 95–104
- pauci-immune necrotizing, clinicopathologic predictors for, 29–37

Glomerulosclerosis

- in diabetic nephropathy, TGF- β polymorphism and, 22–28
- focal segmental. *See* Focal segmental glomerulosclerosis
- Glucose, blood, in uremic diabetic patients, 523–531
- Glucose degradation products, formation during CAPD, S1: 57–60

Glucosuria

- in drug-induced Fanconi syndrome, 292–309
- in patients admitted to inpatient hospital-based facility, 1225–1232

Glue sniffing, Fanconi syndrome and, 292–309

Glycated proteins, in diabetic ESRD patients, 523–531

Glycation profile, in immunoglobulin A nephropathy, 558–564

Graft infection, *Aspergillus*, after cadaveric renal transplant, 488–492

Granulomatous interstitial nephritis

- case study, 714–719
- levofloxacin-induced, E7

Growth factors, in peritoneal dysfunction in CAPD patients, S1:61–67

HD. *See* Hemodialysis

Heart failure

- as cause for hospitalization in chronic dialysis patients, 1267–1277
- congestive. *See* Congestive heart failure

HELP study. *See* Hemodialysis and Estrogen Levels in Postmenopausal Patients (HELP)

Hematocrit

- comparison in different data systems, 433–441

effect of hemoglobin variability on anemia management and, 111–124

outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Hematologic neoplasms, hypouricemia in inpatient hospital-based facility, 1225–1232

Hematuria

- in IgM nephropathy, 343–350
- prevalence among Zuni Indians, 1195–1204

Hemodialysis (HD)

- access. *See* Vascular access
- for acute renal failure after accidental perchloroethylene ingestion, E11
- ambulatory, medication-related problems in, 386–393
- amputation risk factors for, 162–170
- arteriovenous fistula blood flow and resistance during, 132–139
- atherosclerotic cardiovascular disease, dyslipidemia and, S3:22–24
- body fat mass in, S1:137–141
- cardiac valvular disease, calcium-phosphate imbalance in, 411–421
- during cardiopulmonary bypass, outcome/complications of, 1247–1256
- cardiovascular disease mortality, intima-media thickness of carotid artery and, S1:76–79
- carnitine supplementation, S1:116–122
- carotid atherosclerosis, gene polymorphisms and, 822–832
- chronic
 - anemia in, safety of high-dose SFGC for, 651–657
 - deselection for, 723–732
 - heart failure as cause for hospitalization in, 1267–1277
 - LVH and endothelial dysfunction in, 616–623
 - malnutrition and depression in, 1037–1042
 - 22-oxa-1,25-dihydroxyvitamin D₃ for, S1:108–111
- comparison of dual dialyzers in parallel and series, 1008–1015
- and continuous venovenous hemodiafiltration for iodine toxicity, 702–708
- daily
 - for massive uremic tumoral calcinosis, E12
 - nutrition and, S1:112–115
- daytime sleepiness in, 394–402
- for diabetic patients, provision and outcomes of care for, 125–131
- diffuse alopecia caused by tinzaparin, E15
- dose. *See* Dialysis dose
- erythropoietin response, vitamin C and, 1233–1239
- for ESRD
 - effect of socioeconomic status on quality of life, 186–195
 - health-related quality of life in patients of different ethnicities, 605–615
 - negative attitudes toward self-care and, 380–385
 - survival, HIV-associated nephropathy and, 1060–1064
- estimation of delivered dose by UV absorbance, 1026–1036
- evening shift, survival improvement and, 796–806
- homocysteine levels, *N*-acetylcysteine and, 442–446
- hydration status, brain natriuretic peptide and, 1257–1266
- infection risk, iron therapy and, S5:18–25
- limb swelling, acute muscle infarction in diabetic patients, 1322–1326
- lipid-lowering therapy, non-HDL cholesterol as target for, S1:72–75
- lower body negative pressure, hemodynamic response to, 807–813
- maintenance, patient functionality, levocarnitine and, S4:44–48
- morning shift, survival improvement and, 796–806
- mortality, sedentary behavior and, 447–454
- nocturnal
 - for lower-extremity peripheral arterial disease, 225–229
 - nutrition and, S1:112–115
- outcome. *See* Outcome
- for postmenopausal women, estrogen levels in, 1240–1246
- predialysis care, retrospective chart review of, 49–61
- pre-ESRD referral timing and, 310–318
- QT dispersion, intracellular magnesium and, 196–202
- rEPO therapy, mechanisms of, 179–185
- survival, obesity and, 925–932
- uremic patients, restless legs syndrome IN, 833–839
- vascular access thrombosis risk, MTHFR gene polymorphism and, 637–642

Hemodialysis and Estrogen Levels in Postmenopausal Patients (HELP)

- early menopause and hormone use in dialysis-dependent women, 643–650
- low estrogen in postmenopausal hemodialysis-dependent women, 1240–1246

Hemoglobin

- A_{1c}, in diabetic ESRD patients, 523–531
- predialysis anemia survey, 49–61
- restless legs syndrome in uremic hemodialysis patients and, 833–839
- variability, anemia management in ESRD and, 111–124

Hemolytic uremia syndrome (HUS)

- resolution of thrombocytopenia but not hemolysis after interferon- α withdrawal, E10

Hemolytic uremic syndrome (HUS)

- with *Clostridium difficile* colitis, E14
- nondiarrheal, associated with shiga toxin bacteremia and UTI, E4
- post-renal transplant thrombotic microangiopathy and, 471–479
- with typhoid fever, 709–713

Henoch-Schönlein nephritis, group A streptococcal antigen in, 366–370

Hepatic cysts, diagnosis by 18-FDG-PET, E22

Hepatitis B, viral load in dialysis population, biological dynamics of, 1278–1285

Hepatitis C-virus-associated tubulointerstitial injury, 767–775

Hepatocyte growth factor, peritoneal dysfunction in CAPD patients and, S1:61–67

Hepatocytes, in chronic renal failure, cytosolic calcium in, S1:127–132

High performance liquid chromatography, albuminuria in diabetes mellitus, 336–342

Histopathology, of familial focal segmental glomerulosclerosis, 1170–1178

Histoplasmosis, granulomatous interstitial nephritis and, 714–719

HIV-associated nephropathy with ESRD, dialysis modality effect on survival, 1060–1064

HIV infection. *See* Human immunodeficiency virus infection

HMG-CoA reductase inhibitors, for hypercholesterolemic renal transplantation recipients, 1088–1096

Homocysteine

- cardiovascular disease in ESRD and, S1:89–95
- in hemodialysis, *N*-acetylcysteine and, 442–446
- high, vascular thrombosis risk and, 637–642
- prevalence of peripheral arterial calcification in ESRD and, 140–148
- in uremia, S1:123–126

Hospitalization, for ESRD hemolysis patients of different ethnicities, 605–615

Human immunodeficiency virus infection (HIV)

- with ESRD, management of, 279–291
- nephropathy management, 279–291

HUS. *See* Hemolytic uremic syndrome

Hydration status, in hemodialysis, brain natriuretic peptide and, 1257–1266

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA inhibitors), non-HDL cholesterol as target for, S1:72–75

Hyperalbuminemia, hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89–95

Hyperaminoaciduria, in drug-induced Fanconi syndrome, 292–309

Hypercalciuria, in drug-induced Fanconi syndrome, 292–309

Hypercholesterolemia, in renal transplantation recipients, HMG-CoA reductase inhibitors for, 1088–1096

Hyperhomocysteinemia, cardiovascular disease in ESRD, S1:89–95

Hyperkalemia, hemodialysis during cardiopulmonary bypass with potassium-rich cardioplegia, 1247–1256

Hyperoxaluria, in short bowel syndrome, 230–237

Hyperparathyroidism, secondary

- calcimimetics for, S1:104–107
- in chronic hemodialysis, 22-oxa-1,25-dihydroxyvitamin D₃ for, S1:108–111
- new treatment strategies, S1:100–103

Hyperphosphatemia, restless legs syndrome in uremic hemodialysis patients and, 833–839

Hypertension

- in chronic kidney disease prediction, 1–12
- chronic renal transplant dysfunction risk and, 859–867
- control, effect on diabetic nephropathy progression and albuminuria, 13–21
- with diabetes mellitus, protein intake, microalbuminuria and, 580–587
- endothelial dysfunction and LVH in chronic hemodialysis, 616–623
- idiopathic membranous glomerulonephritis prognosis and, 38–48
- left ventricular dysfunction in ESRD and, 1016–1025
- mortality in hemodialysis and, 814–821
- pediatric renal transplant recipients, vascular function in, 684–691

pre-dialysis, survival of hemodialysis patients and, 814–821

protein intake, microalbuminuria and, 580–587

and renovascular disease and renal function in elderly, 990–996

uncontrolled with diabetic nephropathy and renal artery stenosis, 351–359

Hypertriglyceridemia

- treatment, K/DOQI Clinical Practice guidelines for, S3: 39–41
- in uremia, S1:84–88

Hypoalbuminemia in peritoneal dialysis patients, peritonitis prediction and, 664–669

Hypokalemia

- in drug-induced Fanconi syndrome, 292–309
- in patients admitted to inpatient hospital-based facility, 1225–1232

Hypophosphatemia, in patients admitted to inpatient hospital-based facility, 1225–1232

Hypotension

- dialysis-related, lower body negative pressure in HD, 807–813

Hypotension

- intradialytic, dialysis-related carnitine disorder and, 868–876

Hypouricemia, in inpatient hospital-based facility, 1225–1232

I-cell disease, foamy podocytes in, 891–896

Ichthyotoxicosis, from fish gallbladder ingestion, 220–224

Idiopathic glomerulopathies

- clinical picture and long-term prognosis, 343–350
- progression and proteinuria, atorvastatin effects on, 565–570

Idiopathic membranous glomerulonephritis (IMGN)

- PECAM-1 and angiogenic factor expression in, 360–365
- prognosis, focal segmental glomerulosclerosis and, 38–48

Idiopathic nephrotic syndrome, metabolic bone disease risk in children and, 1163–1169

Idiopathic pauci-immune glomerulonephritis, ANCA antigen specificity in, 539–549

Ifosfamide, Fanconi syndrome induction and, 292–309

IgA antiglomerular basement membrane nephritis, Crohn's disease and, 1097–1109

IgA nephropathy. *See* Immunoglobulin A nephropathy

IgM nephropathy, clinical picture and long-term prognosis, 343–350

Iliac artery pseudoaneurysm, after cauteric renal transplant, 488–492

IMGN. *See* Idiopathic membranous glomerulonephritis

Imidazolone

- formation during CAPD, S1:57–60
- peritoneal dysfunction in CAPD patients and, S1:61–67

Immune-complex mediated disease, Henoch-Schönlein nephritis as, 366–370

Immunoglobulin A nephropathy

- glycation profile in, 558–564
- low-dose prednisolone for, 972–983
- progression, INF- γ and IL-4 gene polymorphisms and, 371–379
- therapeutic options, survey of, 1129–1139

Immunoglobulin G, urinary excretion in predicting FSGS outcome, 328–335

Immunohistochemistry, hepatitis C virus-associated tubulointerstitial injury, 767–775

Immunosuppression

- adenovirus infection of renal allograft and, 696–701
- calcineurin-inhibitor-based, thrombotic microangiopathy after, 471–479
- influence on dyslipidemia, S3:36
- post-renal transplant prediction of nonmelanoma skin cancer, 676–683

Index of Coexistent Disease (ICED), changes over chronic dialysis therapy, prognostic importance of, 149–161

Indoxyl sulfate

- binding, effect of tryptophan metabolism in uremia, S1:38–41
- removal, effects on gene expression in uremic kidney, S1:8–14
- serum levels in hemodialysis, *bifidobacterium* and, S1:142–145

Infants, continuous renal replacement therapy for, 984–989

Inferior vena caval diameter, hydration status in hemodialysis and, 1257–1266

Inflammation

- chronic, in ESRD PD patients, coronary artery calcification and, 203–211
- hyperhomocysteine in cardiovascular disease of ESRD and, S1:89–95
- soluble Fas as predictor of atherosclerosis in ESRD, 1043–1051

Inflammatory bowel disease, IgA antiglomerular basement membrane nephritis and, 1097–1109

Inflammatory markers, residual renal function in CRF and, 1212–1218

Inherited glomerular disease

- nonmuscle myosin IIA abnormality in, 95–104
- recurrence of FSGS after pediatric renal transplant, 1314–1321

In situ hybridization, hepatitis C virus-associated tubulointerstitial injury, 767–775

Insulin resistance

- chronic renal transplant dysfunction and, 859–867
- left ventricular hypertrophy in type 1 PKD and, 1219–1224

Interferon- α withdrawal, resolution of thrombocytopenia in HUS, E10

Interferon- γ gene polymorphism, IgA nephropathy progression and, 371–379

Interleukin-6

- acute renal failure with septic shock and, 62–75
- prediction of ARF after allograft ischemic injury, 1074–1087

Interleukin-8, prediction of ARF after allograft ischemic injury, 1074–1087

Interleukin-4 gene polymorphism, immunoglobulin A nephropathy progression and, 371–379

Interleukin-1 proinflammatory genotype, in proteinase 3-ANCA vasculitis, 933–942

Interleukin-1 receptor antagonist, proinflammatory genotype in proteinase 3-ANCA vasculitis, 933–942

Intermediate-density lipoprotein cholesterol, as target for lipid-lowering therapy in dialysis, S1:72–75

Interstitial fibrosis

- chemokines and chemokine receptors in, S1:15–18
- outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Interstitial nephritis, adenovirus infection of renal allograft, 696–701

Inulin

- in cirrhotic patients, 269–278
- clearance, compared with iothalamate clearance in CKD, 752–759

Iodine toxicity, hemodialysis and continuous venovenous hemodiafiltration for, 702–708

Iothalamate clearance technique, for GFR measurement in chronic kidney disease, 752–759

Iron, in atherosclerosis, S1:80–83

Iron deficiency anemia, in chronic hemodialysis, high-dose sodium ferric gluconate complex for, 651–657

Iron dextran

- compared to high-dose SFGC infusion for chronic hemodialysis patients, 651–657
- safety profile, S5:18–25

Iron gluconate, in chronic hemodialysis, safety of, 651–657

Iron sucrose

- safety in chronic hemodialysis, 651–657
- safety profile, S5:18–25

Iron therapy

- effect of hemoglobin variability on, 111–124
- intravenous, safety in, S5:18–25
- safety of high-dose SFGC infusion for chronic hemodialysis patients, 651–657

Ischemic nephropathy, blood pressure and renal function in elderly, 990–996

Japanese patients, gene polymorphisms and IgA nephropathy progression, 371–379

K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease

- assessment of dyslipidemias, S3:22–38
- development, methods for, S3:17–21
- evidence, S3:21
- intended users, S3:15–17
- methods for review of articles, S3:61–69
- rationale for, S3:11–13
- research recommendations, 59–60, S3:21
- scope, S3:14–15
- target population, S3:13–14
- therapeutic lifestyle changes for CKD, S3:69–70
- treatment of dyslipidemias, S3:39–58
- updates, anticipated, S3:17

K/DOQI Outcome Quality Initiative guidelines

- iron therapy safety, S5:18–25
- meeting challenges of, S5:3–10

Keto acids, metabolic effect in CRF patients on low-protein diet and erythropoietin, S1:26–30

Kidney disease. *See also specific kidney diseases*

- prevalence among Zuni Indians with/without diabetes, 1195–1204

Kidney function tests, in cirrhotic patients, 269–278

Kidney-pancreas transplant
de novo thrombotic microangiopathy and, 471–479
pancreaticoduodenectomy leak, culture-negative peritonitis and, E19

Kidney senescence, chronic allograft nephropathy, cyclin-dependent kinase inhibitor genes and, 1303–1313

Knowledge barrier, for self-care dialysis in ESRD, 380–385

Kt/V, improvement after peritoneal dialysis prescription change, 840–848

Lactate dehydrogenase, prediction of ARF after allograft ischemic injury, 1074–1087

L-Carnitine. *See* Levocarnitine

Lean body mass, in hemodialysis patients, S1:137–141

Left ventricular dysfunction, subclinical, risk factors in ESRD, 1016–1025

Left ventricular hypertrophy (LVH)
and endothelial dysfunction in chronic hemodialysis, 616–623
risk, advanced glycation end products and, S1:52–56
in type 1 PKD, insulin resistance and, 1219–1224

Left ventricular mass
insulin resistance in polycystic kidney disease type I and, 1219–1224
left ventricular dysfunction in ESRD and, 1016–1025

Leptin, chronic inflammation in ESRD PD patients and, 203–211

Levocarnitine
for chronic hemodialysis patients, S4:4–12
for dialysis-related carnitine disorder, 868–876
for myocardial dysfunction, S4:35–43
patient functionality in maintenance hemodialysis, S4:44–48
pharmacology, dialysis-related carnitine disorder and, S13–26

Levofloxacin, induction of granulomatous interstitial nephritis, E7

Light-and-heavy-chain deposition disease, case study, 508–517

Limb swelling, in hemodialysis patients, diabetic muscle infarction and, 1322–1326

Lipid-lowering therapy
in dialysis patients, non-HDL cholesterol as target for, S1:72–75
for lipoprotein glomerulopathy, 244–249

Lipid metabolism
carnitine supplementation in hemodialysis, S1:116–122
in liver of chronic renal failure patient, S1:127–132

Lipidoses, foamy podocytes in, 891–896

Lipid peroxidation, carnitine in, S4:4–12

Lipogenesis, in development of uremic hyperlipidemia, S1:84–88

Lipoprotein(a), prevalence of peripheral arterial calcification in ESRD and, 140–148

Lipoprotein glomerulopathy, intensive lipid-lowering therapy for, 244–249

Liver disease, assessing renal function in, 269–278

Liver function tests, in cirrhotic patients, 269–278

Liver metabolism, in chronic renal failure, S1:127–132

L-Lysine, Fanconi syndrome and, 292–309

Losartan, diabetes nephropathy progression and, S1:22–25

Low-calorie diet, for overweight chronic proteinuric nephropathy patients, 319–327

Low-density lipoprotein (LDL)
calculation, Friedewald formula for, S3:34–35
high, K/DOQI Clinical Practice guidelines for treating, S3:534–534

oxidation in atherosclerosis, iron and, S1:80–83
as target for lipid-lowering therapy in dialysis patients, S1:72–75

Lower body negative pressure in hemodialysis, hemodynamic response to, 807–813

Low-protein diet
control of chronic rejection in kidney transplant recipients, S1:146–152
with keto acids and erythropoietin for CRF patients, S1:26–30
with oral carbon adsorbent, effect on creatinine slope in CRF, S1:35–37
for very late stage CRF, S1:31–34

Lupus anticoagulant, in antiphospholipid syndrome, 1205–1211

Lupus nephritis, in children, renal transplantation for, 455–463

Lymphangioleiomyomatosis, renal angiomyolipoma and, 877–883

Lymphokines. *See also* specific lymphokines
prediction of ARF after allograft ischemic injury, 1074–1087

Macromolecule hypomethylation, homocysteine in uremia, S1:123–126

Macrophages, in crescentic glomerulonephritis, 950–961

Magnesium, intracellular, QT dispersion in hemodialysis patients and, 196–202

Malacoplakia, renal parenchymal, causing acute renal failure, E21

Male vasculature, arteriovenous fistula placement and, 429–432

Malnutrition
and depression in chronic hemodialysis patients, 1037–1042
hyperhomocysteinemia in cardiovascular disease of ESRD and, S1:89–95

Mast cells, crescentic glomerulonephritis and, 785–795

Maxacalcitol, for secondary hyperparathyroidism, S1:100–103

Maximal glomerular hypertrophy, in nephropenic focal segmental glomerulosclerosis, 1179–1188

MCD. *See* Minimal change disease

MDRD. *See* Modification of Diet in Renal Disease

Mean arterial pressure. *See* Blood pressure

Mechanical stretch, diabetic nephropathy progression and, S1:19–21

Mediastinal irrigation, dialytic therapy for iodine toxicity from, 702–708

Medical Outcomes Study 30-Item Short Form
health-related quality of life in ESRD, 596–604
impact of socioeconomic status on ESRD quality of life, 186–195

prediction of morbidity/mortality in dialysis patients, 1286–1292

Medicare
effect of hemoglobin variability on anemia management and, 111–124
national EPO reimbursement policy, 254–258

Medication-related problems, in ambulatory hemodialysis, 386–393

Membranous nephropathy
in antiphospholipid syndrome, 1205–1211
caused by skin whitening cream, 250–253
prognosis, focal segmental glomerulosclerosis and, 38–48

Meningeal cysts, multiple thoracic paraspinal in ADPKD, E8

Menopause. *See also* Postmenopausal women
early onset, in dialysis-dependent women, 643–650

Mental Component Summary, prediction of morbidity/mortality in dialysis patients, 1286–1292

Mental function monitoring, in dialysis patients, 1286–1292

Mercaptopurine, Fanconi syndrome induction and, 292–309

Mercury poisoning, causing membranous nephropathy, 250–253

Mesangial C3 nephropathy, in antiphospholipid syndrome, 1205–1211

Mesangial glomerulonephritis, clinical picture and long-term prognosis, 343–350

Meta-analysis, of therapeutic options for IgA nephropathy, 1129–1139

Metabolic bone disease risk, in children with idiopathic nephrotic syndrome, 1163–1169

Metabolic control, in diabetic ESRD patients, 523–531

Methyl-3-chromone, Fanconi syndrome induction and, 292–309

Methylentetrahydrofolate reductase gene polymorphism
susceptibility to diabetic nephropathy in type 1 diabetes and, 1189–1194
vascular access thrombosis risk in hemodialysis, 637–642

Michaelis-Gutman bodies, renal parenchymal malacoplakia causing ARF, E21

Microalbuminuria
central fat distribution and, 733–741
high-normal blood pressure and, 588–595
protein intake in healthy adults and, 580–587

α_1 -Microglobulin, urinary excretion in predicting FSGS outcome, 328–335

Microscopic polyangiitis, proinflammatory IL-1 β /IL-1 α genotype and, 933–942

Middle molecules, comparison of dual dialyzers in parallel and series, 1008–1015

Minimal change disease (MCD)
in antiphospholipid syndrome, 1205–1211
nephrotic syndrome with acute renal failure in diabetes mellitus, 1327–1333

Mitochondriopathy, asymptomatic proteinuria and hearing loss in, 259–264

Mitogen-activated protein kinase, progression of diabetic nephropathy, S1:19–21

Modification of Diet in Renal Disease (MDRD)
GFR estimation equation, 1–12
high urine volume and low urine osmolality as risk factors, 962–971

Monoclonal immunoglobulin deposition disease (MIDD), case study, 508–517

Morbidity, time of day for hemolysis and, 796–806

Mortality
diabetic nephropathy susceptibility in type 1 diabetes, methylenetetrahydrofolate reductase gene polymorphism and, 1189–1194
of dialysis patients, sedentary behavior and, 447–454
for ESRD hemolysis patients of different ethnicities, 605–615
in hemodialysis, hypertension and, 814–821
prediction, in ARF of septic shock, tumor necrosis factor- α receptors and, 62–75
pre-ESRD referral timing and, 310–318
time of day for hemolysis and, 796–806

Mucolipidosis type II, foamy podocytes in, 891–896

Muscle infarction, limb swelling in diabetic hemodialysis patients and, 1322–1326

Muscle weakness, of dialysis-related carnitine disorder, L-carnitine for, 868–876

Myeloma tubulopathy, caused by monoclonal V κ light chain, 497–504

Myelo-monocytic infiltrate, in lower esophagus of pediatric renal transplant recipient, E16

Myocardial contractility, dialysis-related hypotension and, 807–813

Myocardial Doppler velocity, left ventricular dysfunction in ESRD and, 1016–1025

Myocardial infarction, levocarnitine therapy for, S4:35–43

Myocarditis, hemolytic uremic syndrome with typhoid fever and, 709–713

NAC (*N*-acetylcysteine), plasma homocysteine levels in HD and, 442–446

National Health and Nutrition Survey III (NANES III), microalbuminuria and protein intake in healthy adults, 580–587

Necrotizing tracheitis, pediatric, EBV load determination for, 212–219

Needle phobia, as barrier for self-care dialysis in ESRD, 380–385

Nephrectomy, living donors, patient attitudes on, 849–858

Nephritis, tubulointerstitial, hepatitis C-virus associated, 767–775

Nephritis-associated plasmin receptor, in Henoch-Schönlein nephritis, 366–370

Nephrolithiasis, in short bowel syndrome, conjugated bile acid replacement therapy and, 230–237

Nephrologists
exercise counseling by, 171–178
in improving outcome for chronic kidney disease, 903–924

Nephrology decision-making, controversies in, 723–732

Nephropathy, antiphospholipid antibody-associated, 1205–1211

Nephropenia in FSGS, glomerular basement membrane length to podocyte ratio, 1179–1188

Nephrotic syndrome
with acute renal failure in diabetes mellitus, 1327–1333
in children, long-course prednisolone regimens for, 1155–1162
idiopathic, metabolic bone disease risk in children and, 1163–1169

in IgM nephropathy, 343–350
in lipoprotein glomerulopathy, lipid-lowering therapy for, 244–249

Nephrotoxicity
bisphosphonate, mechanisms of, E18
from fish gallbladder ingestion, 220–224

NephTrak, URR and hematocrit values compared with different data systems, 433–441

Newborns, continuous renal replacement therapy for, 984–989

Niceritrol, in lipid-lowering therapy for lipoprotein glomerulopathy, 244–249

Nocturnal hemodialysis, daytime sleepiness in CRF and, 403–410

Nodular glomerulosclerosis, case study, 508–517

Nondiabetic kidney disease, prevalence among Zuni Indians, 1195–1204

Nonmelanoma skin cancer, prediction after renal transplantation, 676–683

Nonmuscle myosin IIA abnormality, in Fechtner syndrome, 95–104

North American Indians, prevalence of hematuria with/without diabetes, 1195–1204

NPHS2 (gene for steroid resistant nephrotic syndrome 2), in focal segmental glomerulosclerosis, 1170–1178

Nuclear factor- κ B, progression of chronic kidney disease, S1:3–7

Nucleic acid amplification, determination of HBV viral load in dialysis patients, 1278–1285

Nutrition
daily hemodialysis and, S1:112–115
depression with malnutrition in chronic hemodialysis patients and, 1037–1042
dietary AGEs, effect on rat remnant kidney model, S1:48–51
malnutrition and depression in chronic hemodialysis patients, 1037–1042
nocturnal hemodialysis and, S1:112–115
obesity effect on dialysis survival, 925–932
oral nutritional supplementation for peritoneal dialysis, 658–663
protein intake for dialysis patients, S1:133–136

Nutritional status
balancing dialysis dose and protein intake for dialysis patients, S1:133–136
body fat mass in hemodialysis, S1:137–141
low-protein intake for rejection control in kidney transplant recipients, S1:146–152
in short bowel syndrome, conjugated bile acid replacement therapy and, 230–237

Obesity
central fat distribution relationship to renal function impairment, 733–741
chronic renal transplant dysfunction risk and, 859–867
dialysis survival and, 925–932
renal transplantation and, 480–487

Obstructive jaundice, hypouricemia in inpatient hospital-based facility, 1225–1232

O-glycans, in immunoglobulin A nephropathy, 558–564

OPD-9195, progression of nephropathy and, S1:68–71

Open-heart surgery, acute renal failure after, 724–751

Oral absorbent
effect on tryptophan metabolism in uremia, S1:38–41
with low-protein diet, effect on creatinine slope in CRF, S1:35–37

Organic anion transporter in uremia, AST-120 effects on, S1:8–14

Organ transplant recipients, quantitative tissue EBV polymerase chain reaction in, 212–219

Orlistat, interaction with cyclosporine in renal transplant patient, 493–496

Osmolality of urine, progression of renal disease and, 962–971

Osteocalcin, in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997–1007

Osteoporosis
risk in children with idiopathic nephrotic syndrome, 1163–1169
steroid-sensitive nephrotic syndrome in adults and, 550–557

Outcome
adenovirus infection of renal allograft, 696–701
in ANCA-associated glomerulonephritis, 532–538
Churg-Strauss angiitis, 5-year retrospective study, 776–784
improvement, in chronic kidney disease, 903–924
peritoneal clearance *vs.* residual renal function and, 1293–1302
prediction, in pauci-immune necrotizing glomerulonephritis, 29–37

Overhydration, in hemodialysis, brain natriuretic peptide and, 1257–1266

Overweight
central fat distribution relationship to renal function impairment, 733–741
chronic proteinuric nephropathy patients, weight loss benefits for, 319–327
renal transplantation and, 480–487
survival on dialysis and, 925–932
type II diabetic on PD, drug interaction in renal transplant patient, 493–496

22-Oxa-1,25-dihydroxyvitamin D₃, for chronic hemodialysis, S1:108–111

Oxalate excretion, in short bowel syndrome, conjugated bile acid replacement therapy and, 230–237

Pamidronate, short-term high-dose-induced acute tubular necrosis, E18

Pancreas transplantation, survival, for type 1 diabetes with renal failure, 464–470

Pancreaticoduodenectomy leak, after pancreas transplant, culture-negative peritonitis and, E19

Parathyroid hormone (PTH)
calcium-phosphate imbalance in cardiac valvular disease and, 411–421
cystosolic calcium in hepatocytes in CRF and, S1:127–132
in diagnosis of renal osteodystrophy in predialysis ESRD patients, 997–1007

in secondary hyperparathyroidism, calcimimetics in, S1:104–107

Patient attitudes, about living donor transplants and living donor nephrectomy, 849–858

Pauci-immune crescentic glomerulonephritis, in antiphospholipid syndrome, 1205–1211

Pauci-immune necrotizing glomerulonephritis, clinicopathologic predictors, 29–37

Pediatric patients. *See* Children

Pedigrees, for familial focal segmental glomerulosclerosis, 1170–1178

Perchloroethylene ingestion, acute renal failure requiring hemodialysis, E11

Periodic limb movements, daytime sleepiness in CRF and, 403–410

Peripheral arterial calcifications, prevalence/progression in ESRD, 140–148

Peripheral arterial disease (PAD), lower-extremity, nocturnal hemodialysis for, 225–229

Peripheral blood mononuclear cells, intracellular magnesium, QT dispersion in hemodialysis and, 196–202

Peripheral vascular disease (PWD), amputation risk for hemodialysis patients, 162–170

Peritoneal clearance, *vs.* residual renal function for patient survival and quality of life, 1293–1302

Peritoneal dialysis (PD)

- adequacy. *See* Adequacy, peritoneal dialysis
- albumin levels, in predicting peritonitis, 664–669
- atherosclerotic cardiovascular disease, dyslipidemia and, S3:24
- continuous ambulatory. *See* Continuous ambulatory peritoneal dialysis
- culture-negative peritonitis, pancreaticoduodenocystotomy leak of pancreas transplant and, E19
- effect on HIV-associated nephropathy ESRD survival, 1060–1064
- for ESRD, chronic inflammation in, coronary artery calcification and, 203–211
- inadequate, prescription changes for, 840–848
- mortality, sedentary behavior and, 447–454
- oral nutritional supplementation for, 658–663
- peritonitis aminoglycoside therapy, residual renal function unaltered by, 670–675
- predialysis care, retrospective chart review of, 49–61
- pre-ESRD referral timing and, 310–318
- prescription change, for inadequacy, 840–848
- survival

 - obesity and, 925–932
 - peritoneal clearance *vs.* residual renal function and, 1293–1302
 - for type II diabetes mellitus, drug interaction in renal transplant patient, 493–496

Peritoneal dysfunction, in CAPD patients, growth factors and AGEs in, S1:61–67

Peritonitis

- aminoglycoside therapy, residual renal function unaltered by, 670–675
- culture-negative, pancreaticoduodenocystotomy leak of pancreas transplant and, E19
- prediction, hypoalbuminemia in peritoneal dialysis patients and, 664–669
- p16 expression, in aging kidney and chronic allograft nephropathy, 1303–1313
- p27 expression, in aging kidney and chronic allograft nephropathy, 1303–1313

Pharmacokinetics, drug interaction in renal transplant patient, 493–496

Pheochromocytomas, with von Hippel-Lindau gene mutations, E3

Phosphate

- in cardiac valvular disease in hemodialysis patients, 411–421
- wasting, in drug-induced Fanconi syndrome, 292–309

Phosphorus

- daily hemodialysis and, S1:112–115
- metabolic alterations, promotion of cardiovascular disease in CKD, S5:11–17
- restless legs syndrome in uremic hemodialysis patients and, 833–839
- in secondary hyperparathyroidism, calcimimetics in, S1:104–107
- serum, amputation risk for hemodialysis patients, 162–170
- uremic vascular calcifications in ESRD, S1:96–99

Phosphorus binders, non-calcium-containing, for secondary hyperparathyroidism, S1:100–103

Physical Component Summary, prediction of morbidity/mortality in dialysis patients, 1286–1292

Physical function, monitoring in dialysis patients, SF-36 for, 1286–1292

Physicians

- primary care, in improving outcome for chronic kidney disease, 903–924
- referral patterns, for predialysis patients, 49–61

Plasma exchange, post-renal transplant thrombotic microangiopathy and, 471–479

Plasma protein binding, effect of tryptophan metabolism in uremia, S1:38–41

Platelet endothelial cell adhesion molecule-1 (PECAM-1), in idiopathic membranous nephropathy, 360–365

Pneumocystis carinii pneumonia, in non-HIV hemodialyzed patient, atovaquone for, E13

Podocin

- in focal segmental glomerulosclerosis, 1170–1178
- gene mutations, post-transplant FSGS recurrence, 1314–1321
- in pathophysiology of Alport-like syndrome, 95–104

Podocytes

- foamy, in renal lipidoses, 891–896
- hypertrophy, FSGS development in nephronopenia, 1179–1188

Polyangiitis, outcome, 5-year retrospective study, 776–784

Polyclystic kidney disease (PKD)

- autosomal dominant. *See* Autosomal dominant polycystic kidney disease
- D298 ENOS polymorphism in, 90–94
- high urine volume and low urine osmolality as risk factors in, 962–971
- type I, D298 ENOS polymorphism in, 90–94

Polymerase chain reaction (PCR)

- determination of HBV viral load in dialysis patients, 1278–1285
- tissue EBV, for pediatric solid organ recipients, 212–219

Polyuria, in drug-induced Fanconi syndrome, 292–309

Population-based studies
of health-related quality of life in ESRD, 596–604
prevalence of hematuria among Zuni Indians with/without diabetes, 1195–1204

Positron emission tomography, 18-FDG, diagnosis of renal and hepatic cysts in ADPKD, E22

Postmenopausal women
dialysis-dependent, early onset menopause and use in, 643–650
on hemodialysis, estrogen levels in, 1240–1246

Posttransplant recurrence of renal disease, podocin gene mutations and, 1314–1321

Potassium-rich cardioplegia, hemodialysis during cardiopulmonary bypass and, 1247–1256

Predialysis Survey on Anemia Management (PRESAM), demographics and patient referral data, 49–61

Prediction
of allograft acceptance/function, EC survival programs and, 1140–1154
of ARF after cardiac surgery, 76–83
of nonmelanoma skin cancer after renal transplantation, 676–683
of outcome, in pauci-immune necrotizing glomerulonephritis, 29–37

Prednisolone
long-course regimens for children with nephrotic syndrome, 1155–1162
low-dose, for IgA nephropathy, 972–983

Prevalence
chronic kidney disease, 1–12
of depression in for new dialysis patients, 105–110

Prevention
chronic kidney disease, early referral and, 505–507
exercise counseling by nephrologists, 171–178
K/DOQI Outcome Quality Initiative Guidelines and, S5: 3–10

Probucol, for lipoprotein glomerulopathy, 244–249

Prognosis
IgM nephropathy, 343–350
intima-media thickness of carotid artery in ESRD, S1: 76–79
membranous nephropathy, focal segmental glomerulosclerosis and, 38–48

Progression
atherosclerotic cardiovascular disease, dyslipidemia and, S3:26
atorvastatin effects on, 565–570
chemokines and chemokine receptors in, S1:15–18
of chronic kidney disease, 903–924, S1:3–7
of chronic renal failure
effect of keto acids, erythropoietin and low-protein diet on, S1:26–30
low-protein diet with oral carbon adsorbent and, S1: 35–37
of diabetic nephropathy, 943–949, S1:19–21
high urine volume, low urine osmolality and, 962–971
of immunoglobulin A nephropathy, low-dose prednisolone and, 972–983

Prospective study, post-renal transplant prediction of non-melanoma skin cancer, 676–683

Protein-creatinine ratio
low-dose prednisolone for IgA nephropathy and, 972–983
vs. protein-osmolality ratio for estimating proteinuria, 760–766

Protein-energy malnutrition, at time of renal transplantation, 480–487

Protein intake
carnitine supplementation in hemodialysis, S1:116–122
for dialysis patients, balancing dialysis dose and nutritional status, S1:133–136
low. *See* Low-protein diet
microalbuminuria in healthy adults and, 580–587
oral nutritional supplementation for peritoneal dialysis, 658–663

Protein kinase C, progression of diabetic nephropathy, S1: 19–21

Protein kinase C inhibitor, progression of diabetic nephropathy, S1:19–21

Protein metabolism, in liver of chronic renal failure patient, S1:127–132

Protein-osmolality ratio, vs. protein-creatinine ratio for estimating proteinuria, 760–766

Proteinuria. *See also* Albuminuria
in antiphospholipid syndrome, 1205–1211
asymptomatic, in mitochondrialopathy, 259–264
chronic renal transplant dysfunction risk and, 859–867
diabetic nephropathy progression and, 13–21
in drug-induced Fanconi syndrome, 292–309
estimating in children, 760–766
in IgA nephropathy, therapeutic options for, 1129–1139
in IgM nephropathy, 343–350
and kidney disease progression, atorvastatin effects on, 565–570
weight loss benefits for overweight chronic proteinuric nephropathy patients, 319–327

Protocol biopsies, of stable renal allografts, 1065–1073

Proximal tubular damage, in patients admitted to inpatient hospital-based facility, 1225–1232

PTH. *See* Parathyroid hormone

Pure red blood cell aplasia, after erythropoietin, cyclosporine for, 692–695

QT dispersion in hemodialysis, intracellular magnesium and, 196–202

Quality of care
for anemia, effect of hemoglobin variability on, 111–124
for diabetic hemodialysis patients, 125–131

Quality of life
in ESRD, socioeconomic status and, 186–195
health-related
in ESRD, population-based study of, 596–604
in hemodialysis patients of different ethnicities, 605–615
peritoneal clearance vs. residual renal function and, 1293–1302

Quantitative polymerase chain reaction, for pediatric solid organ recipients, 212–219

Questionnaire, on negative attitudes for self-care dialysis in ESRD, 380–385

Race
acute renal failure after open-heart surgery, 724–751

health-related quality of life for ESRD hemolysis patients, 605–615

Radical nephrectomy, hand-assisted laparoscopic, rhabdomyolysis after, E5

Radioimmunoassay (RIA), albuminuria in diabetes mellitus, 336–342

RAGE (receptor for advanced glycation end products), peritoneal dysfunction in CAPD patients and, S1:61–67

Ranitidine, Fanconi syndrome induction and, 292–309

Rat kidney

- diabetic, OPB-9195 amelioration of glomerular lesions in, S1:68–71
- effects of dietary AGEs on, S1:48–51
- uremic, effects of oral absorbent on gene expression profile in, S1:8–14

Reactive oxygen species, homocysteine in uremia, S1:123–126

Receptor for advanced glycation end products (RAGE), peritoneal dysfunction in CAPD patients and, S1:61–67

Reciprocal creatinine slope, in CRF, effects of low-protein diet with oral carbon adsorbent on, S1:35–37

Recombinant human erythropoietin (rHuEPO)

- erythrocyte expression of complement proteins and, 179–185
- hyporesponsive patients
 - CD34+ cells in, 624–636
 - levocarnitine for, S4:27–34
- with keto acids and low-protein diet for CRF, S1:26–30
- pure red blood cell aplasia after, cyclosporine for, 692–695

Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL), S1:22–25

Referral

- early, in chronic kidney disease, 505–507
- improving outcome in CKD, 903–924
- timing, pre-ESRD and, 310–318

Relapse rate, long-course prednisolone regimens for children with nephrotic syndrome, 1155–1162

Reliability, of URR and hematocrit values, data comparisons, 433–441

Remnant lipoprotein particles, as target for lipid-lowering therapy in dialysis patients, S1:72–75

Renal angiomyolipoma, pulmonary lymphangiomyomatosis and, 877–883

Renal arterial thrombosis, delayed angioplasty after, E20

Renal artery stenosis

- and blood pressure and renal function in elderly, 990–996
- in diabetic nephropathy with uncontrolled hypertension, 351–359

Renal biopsy

- of acute renal failure after fish gallbladder ingestion, 220–224
- allograft dysfunction, drug-induced AIN in, 1116–1121
- antiphospholipid syndrome, 1205–1211
- EBV load determination for, 212–219
- of familial focal segmental glomerulosclerosis, 1170–1178
- granulomatous interstitial nephritis, 714–719
- IgM nephropathy, 343–350
- light-and-heavy-chain deposition disease, 508–517
- mitochondriopathy, 259–264

nephrotic syndrome with acute renal failure in diabetes mellitus, 1327–1333

outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Renal cysts, in ADPKD, diagnosis by 18-FDG-PET, E22

Renal failure. *See* Acute renal failure; Chronic renal failure; End-stage renal disease

Renal functional reserve, in stable allografts, 1065–1073

Renal function impairment, central fat distribution and, 733–741

Renal insufficiency, health-related quality of life in, 596–604

The Renal Network Data System, URR and hematocrit values compared with different data systems, 433–441

Renal osteodystrophy

- diagnostic markers in predialysis ESRD patients, 997–1007
- in uremic patients on maintenance hemodialysis, TRACP and, 1052–1059

Renal parenchymal malacoplakia, causing acute renal failure, E21

Renal replacement therapy. *See also* Hemodialysis; Peritoneal dialysis; specific types of renal replacement therapies

- negative attitudes for self-care dialysis in ESRD, 380–385
- selection, for ESRD with HIV infection, 279–291

Renal transplantation

- cadaveric, pseudoaneurysm of iliac artery and, 488–492
- for children with lupus nephritis, 455–463
- chronic allograft nephropathy in aging kidney, cyclin-dependent kinase inhibitor genes and, 1303–1313
- de novo thrombotic microangiopathy and, 471–479
- endothelial cell survival programs, significance of, 1140–1154
- living donors, living, patient attitudes on, 849–858
- overweight and obesity in, 480–487

Renal transplant recipients

- atherosclerotic cardiovascular disease, dyslipidemia and, S3:24–25
- hypercholesterolemic, HMG-CoA reductase inhibitors for, 1088–1096
- pediatric, acute myelo-monocytic infiltrate in lower esophagus, E16
- pediatric, vascular function in, 684–691
- prediction of nonmelanoma skin cancer in, 676–683
- rejection control, low-protein intake for, S1:146–152
- renal tubular acidosis with repeated rejections and chronic allograft nephropathy, E6
- structural and functional correlations of stable allografts, 1065–1073
- survival, for type 1 diabetes with renal failure, 464–470

Renal tubular acidosis, in renal transplant recipient with repeated rejections and chronic allograft nephropathy, E6

Renal tubular dysfunction in chronic alcohol abuse, Fanconi syndrome and, 292–309

Renal vasculitis, ANCA-associated, 5-year retrospective study of, 776–784

Renovascular disease, and blood pressure and renal function in elderly, 990–996

Residual renal function
in chronic renal failure, circulating inflammatory markers and, 1212–1218
compared with peritoneal clearance for patient survival and quality of life, 1293–1302
in peritonitis after aminoglycoside therapy, 670–675

Restless legs syndrome, in uremic hemodialysis patients, 833–839

Reverse-transcription polymerase chain reaction, hepatitis C virus-associated tubulointerstitial injury, 767–775

Rhabdomyolysis, after hand-assisted laparoscopic radical nephrectomy, E5

Risk assessment, use of comorbidity index for, 149–161

Risk factors
for amputation in hemodialysis, 162–170
for medication-related problems in ambulatory hemodialysis, 386–393
obesity effect on dialysis survival, 925–932

Salicylate intoxication, Fanconi syndrome induction and, 292–309

Salmonella typhi, hemolytic uremic syndrome and, 709–713

Sedentary behavior, decreased survival in dialysis patients and, 447–454

Self-care dialysis, for ESRD, barriers toward, 380–385

Sensorineural hearing loss, *ATP6B1* gene mutations in autosomal recessive distal RTA and, 238–243

Septic shock, acute renal failure, proinflammatory cytokines and, 62–75

Shiga toxin bacteremia
hemolytic uremic syndrome and, 709–713
nondiarrheal hemolytic uremic syndrome with UTI and, E4

Short bowel syndrome, conjugated bile acid replacement therapy for, 230–237

Skin cancer, nonmelanoma, prediction after renal transplantation, 676–683

Skin whitening cream, causing membranous nephropathy, 250–253

Sleepiness, daytime
in chronic renal failure, 403–410
in stable hemodialysis patients, 394–402

Smoking, and albuminuria in prediction of diabetic nephropathy progression, 13–21

Social isolation, as barrier for self-care dialysis in ESRD, 380–385

Socioeconomic status, quality of life in ESRD and, 186–195

Sodium ferric gluconate
in chronic hemodialysis, safety of high dosing, 651–657
safety profile, S5:18–25

Sodium wasting, in drug-induced Fanconi syndrome, 292–309

Soluble Fas, as predictor of atherosclerosis in ESRD, 1043–1051

Soluble tumor necrosis factor- α receptors, prediction of ARF in septic shock, 62–75

Spectrophotometry, estimation of delivered dialysis dose, 1026–1036

Statins, for treating high low-density lipoprotein, S3:41–51

Steatorrhea, in short bowel syndrome, conjugated bile acid replacement therapy for, 230–237

Stem cell factor, crescentic glomerulonephritis and, 785–795

Sternotomy, mediastinal povidone-iodine irrigation iodine toxicity, 702–708

Steroid-sensitive nephrotic syndrome, long-term complications in adults, 550–557

Steroid therapy
for idiopathic nephrotic syndrome in children, metabolic bone disease risk and, 1163–1169
low-dose, for immunoglobulin A nephropathy, 972–983
for proteinuria in IgA nephropathy, 1129–1139

Suramin, Fanconi syndrome induction and, 292–309

Survival
continuous renal replacement therapy for young children and, 984–989
dialysis modality effect on HIV-associated nephropathy ESRD, 1060–1064
of dialysis patients, sedentary behavior and, 447–454
hemodialysis, pre-dialysis hypertension and, 814–821
long-term, kidney–pancreas transplant for type 1 diabetes mellitus and, 464–470
obesity of dialysis patients and, 925–932
pre-ESRD referral timing and, 310–318
renal transplantation for children with lupus nephritis and, 455–463
time of day for hemolysis and, 796–806

Sympathetic tone, dialysis-related hypotension and, 807–813

Tacrolimus, thrombotic microangiopathy after renal transplant and, 471–479

Tartrate-resistant acid phosphatase, uremic patients on maintenance hemodialysis, 1052–1059

Tetracycline, Fanconi syndrome induction and, 292–309

T-help cell subtype balance, IgA nephropathy progression and, 371–379

Therapeutic trial method, significance of morphologic factors for, 38–48

Third National Health and Nutrition Examination Survey (NHANES III), prevalence of chronic kidney disease, 1–12

Three-dimensional magnetic resonance angiography, of renal artery stenosis in diabetic nephropathy with uncontrolled hypertension, 351–359

Thrombi, glomerular lipoprotein, lipid-lowering therapy for, 244–249

Thrombotic microangiopathy, post-renal transplant, 471–479

Thymidine phosphorylase, in idiopathic membranous nephropathy, 360–365

Time of day, effect on hemodialysis survival, 796–806

Tinzaparin, causing diffuse alopecia in HD patient, E15

Transforming growth factor- β gene polymorphisms, diabetic nephropathy and, 22–28
progression of chronic kidney disease, S1:3–7

Treatment algorithm, effect of hemoglobin variability on anemia management and, 111–124

Triglycerides, lipogenesis in uremic hyperlipidemia, S1:84–88

Tryptophan, metabolism in uremia, effect of oral adsorbent on, S1:38–41

Tuberous sclerosis, renal angiomyolipoma, pulmonary lymphangioleiomyomatosis and, 877–883

Tubular defects, in drug-induced Fanconi syndrome, 292–309

Tubular epithelial cells, cell-surface molecules, in crescentic glomerulonephritis, 950–961

Tubular necrosis, outcome prediction in pauci-immune necrotizing glomerulonephritis, 29–37

Tubulointerstitial injury
chemokines and chemokine receptors in, S1:15–18
hepatitis C-virus-associated, 767–775

Tumor necrosis factor- α , 62–75
prediction of ARF after allograft ischemic injury, 1074–1087
progression of chronic kidney disease, S1:3–7

Tumor necrosis factor- α receptors, prediction of ARF in septic shock, 62–75

Typhoid fever, with hemolytic uremic syndrome, 709–713

Ultrasound, of vasculature, gender differences in, 429–432

United States population, prevalence of chronic kidney disease, 1–12

United States Renal Data System, 2002 annual data report, S2:1–256

Urea clearance, comparison of dual dialyzers in parallel and series, 1008–1015

Urea filtration rate/volume, improvement after peritoneal dialysis prescription change, 840–848

Urea reduction ratio, comparison in different data systems, 433–441

Uremia. *See also* End-stage renal disease
carnitine supplementation, S4:4–12
carnitine supplementation in hemodialysis, S1:116–122
daytime sleepiness in CRF and, 403–410
homocysteine in, S1:123–126
hyperlipidemia of, lipogenesis in, S1:84–88
maintenance hemodialysis, TRACP and, 1052–1059
with rHuEPO hyporesponsiveness, levocarnitine for, S4:27–34
tryptophan metabolism, effect of oral adsorbent on, S1:38–41
tumoral calcinosis, daily home hemodialysis for, E12
vascular calcifications in ESRD, S1:96–99

Uric acid wasting, in drug-induced Fanconi syndrome, 292–309

Urinary tract infection, with nondiarrheal hemolytic uremic syndrome, E4

Urinary urate wasting, in patients admitted to inpatient hospital-based facility, 1225–1232

Urine volume, high, progression of renal disease and, 962–971

Vaccinations, in ESRD with HIV infection, 279–291

Vascular access
arteriovenous fistula, vasculature in women and, 429–432
blood flow, for fistulae surveillance, 132–139
for ESRD with HIV infection, 279–291
resistance, blood flow during hemodialysis and, 132–139
surveillance, blood flow and resistance during hemodialysis, 132–139
thrombosis risk in hemodialysis, MTHFR reductase gene polymorphism and, 637–642

Vascular calcifications, in end-stage renal disease, S1:96–99

Vascular endothelial growth factor, in idiopathic membranous nephropathy, 360–365

Vasculature
function, in pediatric renal transplant recipients, 684–691
gender differences for venous access, 429–432

Vasculitides, ANCA-associated, histologic and immunohistologic study of, 539–549

Vasculitis, antiphospholipid antibody-associated, 1205–1211

Venous venous hemofiltration, for infants, 984–989

Vietnam, ichthyotoxic acute renal failure in, 220–224

Vitamin C, effect on EPO response in hemodialysis, 1233–1239

Vitamin D analogues
with calcimimetics, for secondary hyperparathyroidism, S1:104–107
for secondary hyperparathyroidism, S1:100–103

Vkl light chain, in myeloma tubulopathy, 497–504

Waist-hip ratio, renal function impairment and, 733–741

Wegener's granulomatosis
ANCA antigen specificity in, 539–549
outcome, 5-year retrospective study, 776–784
proinflammatory IL-1 β /IL-1 α genotype and, 933–942

Weight
excessive. *See* Obesity
loss, benefits for overweight chronic proteinuric nephropathy patients, 319–327
steroid-sensitive nephrotic syndrome in adults and, 550–557

Wilms' tumor suppresser gene, Alport syndrome-like basement membrane changes in Frasier syndrome, 1110–1115

Women, vasculature of, arteriovenous fistula placement and, 429–432

Xenical, interaction with cyclosporine in renal transplant patient, 493–496

Zopiclone-induced acute interstitial nephritis, E17

Zuni Kidney Project, prevalence of hematuria with/without diabetes, 1195–1204

